<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Infliximab for medical induction of remission in Crohn's disease - Gordon, M - 2023 | Cochrane Library</title> <meta content="Infliximab for medical induction of remission in Crohn's disease - Gordon, M - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012623.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Infliximab for medical induction of remission in Crohn's disease - Gordon, M - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012623.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012623.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Infliximab for medical induction of remission in Crohn's disease" name="citation_title"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="morris@betterprescribing.com" name="citation_author_email"/> <meta content="Vassiliki Sinopoulou" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="Shellie J Radford" name="citation_author"/> <meta content="Nottingham University Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Mohsen Eldragini" name="citation_author"/> <meta content="Nottingham University Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Ana-Maria Darie" name="citation_author"/> <meta content="Nottingham University Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Gordon William Moran" name="citation_author"/> <meta content="University of Nottingham and Nottingham University Hospitals" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012623.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/11/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012623.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012623.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012623.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antimetabolites; *Biosimilar Pharmaceuticals; *Crohn Disease [drug therapy]; Infliximab [therapeutic use]; Purines; Remission Induction" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012623.pub2&amp;doi=10.1002/14651858.CD012623.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012623\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012623\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","ja","hr","fa","fr","pl","hu"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012623.pub2",title:"Infliximab for medical induction of remission in Crohn\u0027s disease",firstPublishedDate:"Nov 20, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012623.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012623.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012623.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012623.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012623.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012623.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012623.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012623.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012623.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012623.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2449 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012623.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0149"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-sec-0143"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/appendices#CD012623-sec-0155"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/supinfo/CD012623-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/supinfo/CD012623-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Infliximab for medical induction of remission in Crohn's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0005">Vassiliki Sinopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0006">Anthony K Akobeng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0007">Shellie J Radford</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0008">Mohsen Eldragini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0009">Ana-Maria Darie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information#CD012623-cr-0010">Gordon William Moran</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information/en#CD012623-sec-0165">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 November 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012623.pub2">https://doi.org/10.1002/14651858.CD012623.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012623-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012623-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012623-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012623-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012623-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012623-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012623-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012623-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012623-abs-0001" lang="en"> <section id="CD012623-sec-0001"> <h3 class="title" id="CD012623-sec-0001">Background</h3> <p>Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor‐alpha (TNF‐α), which is present in high levels in the blood serum, mucosa and stool of people with Crohn's disease. </p> </section> <section id="CD012623-sec-0002"> <h3 class="title" id="CD012623-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of infliximab alone or in combination with another agent for induction of remission in Crohn's disease compared to placebo or active medical therapies. </p> </section> <section id="CD012623-sec-0003"> <h3 class="title" id="CD012623-sec-0003">Search methods</h3> <p>On 31 August 2021 and 4 March 2023, we searched CENTRAL, MEDLINE, Embase, ClinicalTrials.gov and World Health Organization ICTRP. </p> </section> <section id="CD012623-sec-0004"> <h3 class="title" id="CD012623-sec-0004">Selection criteria</h3> <p>Randomised control trials (RCTs) comparing infliximab alone or in combination with another agent to placebo or another active comparator in adults with active Crohn's disease. </p> </section> <section id="CD012623-sec-0005"> <h3 class="title" id="CD012623-sec-0005">Data collection and analysis</h3> <p>Pairs of review authors independently selected studies and conducted data extraction and risk of bias assessment. We expressed outcomes as risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). We assessed the certainty of the evidence using GRADE. </p> <p>Our primary outcomes were clinical remission, clinical response and withdrawals due to adverse events. Our secondary outcomes were endoscopic remission, histological remission, endoscopic response, and serious and total adverse events. </p> </section> <section id="CD012623-sec-0006"> <h3 class="title" id="CD012623-sec-0006">Main results</h3> <p>The search identified 10 RCTs with 1101 participants. They were conducted between 1999 and 2019, and 7/10 RCTs included biologically naive participants. All but one RCT, which did not provide information, were multicentre and funded by pharmaceutical companies, and their authors declared conflicts. The age of the participants ranged from 26 to 65 years. Results were based on one study unless otherwise stated. </p> <p>Infliximab 5 mg/kg to 10 mg/kg may be more effective than placebo at week four for clinical remission (30/55 versus 3/25; RR 4.55, 95% CI 1.53 to 13.50; number needed to treat for an additional beneficial outcome (NNTB) 3) and response (36/55 versus 4/25; RR 4.09, 95% CI 1.63 to 10.25, NNTB 3). The evidence was low certainty. The study did not report withdrawals due to adverse events. </p> <p>We could not draw conclusions on the effects of infliximab 5 mg/kg to 10 mg/kg compared to placebo for fistulating participants for clinical remission (29/63 versus 4/31; RR 3.57, 95% CI 1.38 to 9.25; NNTB 4), response (48/106 versus 15/75; RR 1.94, 95% CI 1.10 to 3.41; NNTB 6; 2 studies) or withdrawals due to adverse events (2/63 versus 0/31; RR 2.50, 95% CI 0.12 to 50.54). The evidence was very low certainty. </p> <p>Infliximab used in combination with purine analogues is probably more effective than purine analogues alone for clinical remission at weeks 24 to 26 (182/301 versus 95/302; RR 1.92, 95% CI 1.59 to 2.32, NNTB 4; 4 studies; moderate‐certainty evidence) and clinical response at week 26 (107/177 versus 66/178; RR 1.64, 95% CI 1.31 to 2.05; NNTB 5; 2 studies; moderate‐certainty evidence). There may be little or no difference in withdrawals due to adverse events at week 26 (62/302 versus 53/301; RR 0.87, 95% CI 0.63 to 1.21; 4 studies; low‐certainty evidence). </p> <p>Infliximab alone may be more effective than purine analogues alone at week 26 for clinical remission (85/177 versus 57/178; RR 1.50, 95% CI 1.15 to 1.95; NNTB 7; 2 studies) and response (94/177 versus 66/178; RR 1.44, 95% CI 1.13 to 1.82; NNTB 7; 2 studies). There may be little or no difference in withdrawals due to adverse events (30/177 versus 43/178; RR 0.70, 95% CI 0.46 to 1.06; 4 studies). The evidence was low certainty. </p> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to 10 mg/kg for clinical remission (19/27 versus 11/28; RR 1.79, 95% CI 1.06 to 3.02) and response (22/27 versus 24/28; RR 1.63, 95% CI 1.08 to 2.46). The evidence was very low certainty. Withdrawals due to adverse events were not reported. </p> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to 10 mg/kg in an exclusively fistulating population for clinical remission (17/31 versus 12/32; RR 1.46, 95% CI 0.84 to 2.53), response (21/31 versus 18/32; RR 1.20, 95% CI 0.82 to 1.78), or withdrawals due to adverse events (1/31 versus 1/32; RR 1.03, 95% CI 0.07 to 15.79). The evidence was very low certainty. </p> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to 20 mg/kg for clinical remission (19/27 versus 11/28; RR 1.79, 95% CI 1.06 to 3.02) or response (22/27 versus 18/28; RR 1.27, 95% CI 0.91 to 1.76). The evidence was very low certainty. Withdrawals due to adverse events were not reported. </p> <p>We could not draw any conclusions on the effects of infliximab 10 mg/kg compared to 20 mg/kg for clinical remission (11/28 versus 11/28; RR 1.00, 95% CI 0.52 to 1.92) or response (14/28 versus 18/28; RR 0.78, 95% CI 0.49 to 1.23). The evidence was very low certainty. Withdrawals due to adverse events were not reported. </p> <p>There may be little or no difference between infliximab and a CT‐P13 biosimilar at week six for clinical remission (47/109 versus 49/111; RR 0.98, 95% CI 0.72 to 1.32), response (67/109 versus 70/111; RR 0.97, 95% CI 0.79 to 1.20) and withdrawals due to adverse events (21/109 versus 17/111; RR 1.26, 95% CI 0.70 to 2.25). The evidence was low certainty. </p> </section> <section id="CD012623-sec-0007"> <h3 class="title" id="CD012623-sec-0007">Authors' conclusions</h3> <p>Infliximab in combination with purine analogues is probably more effective than purine analogues alone in inducing clinical remission and clinical response. Infliximab alone may be more effective in inducing clinical remission and response than purine analogues alone or placebo. Infliximab may be similar in efficacy to a CT‐P13 biosimilar and there may be little or no difference in withdrawals due to adverse events. </p> <p>We were unable to draw meaningful conclusions as to whether infliximab alone is effective when used for exclusively fistulating populations. </p> <p>There was evidence that there may be little or no difference in withdrawal due to adverse events between infliximab plus purines compared with purines alone, as well as infliximab alone compared with purines alone. Meaningful conclusions cannot be drawn on all other outcomes related to adverse events due to very low certainty evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012623-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012623-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012623-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012623-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012623-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012623-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD012623-abs-0018">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012623-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012623-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012623-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012623-abs-0017">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD012623-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012623-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012623-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012623-abs-0002" lang="en"> <h3>Infliximab for the treatment of active Crohn's disease</h3> <p><b>Key messages</b> </p> <p>– Infliximab used with purine analogues (azathioprine or 6‐mercaptopurine) is probably more effective than purine analogues alone at getting Crohn's into remission. It may also be better at improving symptoms. The two treatments may be similar in terms of safety. </p> <p>– Infliximab alone may be more effective than purine analogues alone for getting Crohn's into remission and improving symptoms. The two treatments may be similar in terms of safety. </p> <p>– Infliximab may be as effective as the biosimilar at getting Crohn's into remission and improving symptoms. The two treatments may be similar in terms of safety. An infliximab biosimilar is a biological medicine (contains substances that have been created by using living cells or organisms) that is highly similar to the original brand of infliximab. </p> <p><b>What is Crohn's disease?</b> </p> <p>Crohn's disease is a life‐long inflammatory disease that can affect any part of the gut. Common symptoms include bloody poo, diarrhoea, stomach ache, fever, weight loss and fatigue. We do not know exactly what causes Crohn's, but it is probably a mix of genes, problems with the immune system (which defends the body against infection), bacteria in the gut and something in the environment. </p> <p>There is no known cure for Crohn's, but the symptoms are usually managed with medicines, such as corticosteroids and immune system medications, and sometimes surgery. Infliximab is a type of Crohn's medicine called a biological medicine. </p> <p>Most people with Crohn's have times when they have symptoms and other times when their symptoms are under control. When they have symptoms, it is called active disease. When their symptoms are under control, it is called remission. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out how infliximab compares to other medicines or dummy treatment (placebo) for getting Crohn's into remission or improving symptoms. We also wanted to find out how safe it is compared to other medicines. </p> <p><b>What did we do?</b> </p> <p>We searched for randomised controlled trials (studies where people are assigned to one of two or more treatment groups using a random method) comparing infliximab with any other medical treatment in adults with Crohn's disease. </p> <p><b>What did we find?</b> </p> <p>We found 10 studies including 1101 participants. They looked at:</p> <p>– infliximab compared to placebo (one study);</p> <p>– infliximab plus purine analogues compared to purine analogues alone (four studies);</p> <p>– infliximab compared to purine analogues (medicines called azathioprine or 6‐mercaptopurine) (two studies); </p> <p>– infliximab compared to a biosimilar (one study);</p> <p>– different doses of infliximab compared to each other (two studies).</p> <p>Two studies looked at people with Crohn's disease who had fistulas. A fistula is a narrow tunnel that can develop between your gut and your skin or another organ, such as your bladder. </p> <p><b>Main results</b> </p> <p>Infliximab plus purine analogues (azathioprine or 6‐mercaptopurine) is probably more effective than purine analogues alone at getting Crohn's into remission after 24 to 26 weeks of treatment. It may also be better at improving symptoms. The two treatments may be similar in terms of side effects. </p> <p>Infliximab alone may be more effective than purine analogues alone for getting Crohn's into remission and improving symptoms after 26 weeks of treatment. The two treatments may be similar in terms of side effects. </p> <p>Infliximab may be as effective as the biosimilar at getting Crohn's into remission and improving symptoms after six weeks of treatment. The two treatments may be similar in terms of side effects. </p> <p>There is not enough evidence to compare the other treatments we looked at in this review. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The evidence is mostly of low and very low quality. This is because of problems with the way the trials were carried out, the small number of people who took part and problems with how the results were reported. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>This review is up‐to‐date to 4 March 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012623-sec-0149" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012623-sec-0149"></div> <h3 class="title" id="CD012623-sec-0150">Implications for practice</h3> <section id="CD012623-sec-0150"> <p>Infliximab alone may be more effective in inducing clinical remission and response than placebo (low‐certainty evidence). </p> <p>Infliximab in combination with purine analogues is probably more effective than purine analogues alone in inducing clinical remission (moderate‐certainty evidence) and clinical response (moderate‐certainty evidence). </p> <p>Infliximab alone may be more effective in inducing clinical remission and response than purine analogues alone (low‐certainty evidence). </p> <p>Infliximab may be similar in efficacy to the CT‐P13 biosimilar and there may be little or no difference in withdrawals due to adverse events. </p> <p>We were unable to draw meaningful conclusions whether infliximab alone is effective when used for exclusively fistulating populations. </p> <p>There was evidence of little or no difference in withdrawal due to adverse events between infliximab and purines compared with purines alone, as well as infliximab alone compared with purines alone. Meaningful conclusions cannot be drawn on all other outcomes related to adverse events due to very low‐certainty evidence. </p> </section> <h3 class="title" id="CD012623-sec-0151">Implications for research</h3> <section id="CD012623-sec-0151"> <p>There does not appear to be a role for further studies comparing infliximab with placebo. Whilst the certainty of such outcomes is low, this is not a clinically meaningful comparison in research or practice. Rather, further targeted and appropriately designed randomised controlled trials may be needed to address the gaps in the evidence base in relation to active comparators. It is key that concurrent therapies and prior exposure to biological therapies are considered in the recruitment and design of studies and that these are clearly reported. </p> <p>Other key future research would be comprehensive reporting on the effects of infliximab on endoscopic and histological remission, as these outcomes are rarely reported. </p> <p>Appropriate powering and design of these studies based on appropriate minimum clinical difference data is needed to solve the issue with imprecision in outcomes and add more certainty to the evolving evidence base (<a href="./references#CD012623-bbs2-0072" title="GordonM , LakuninaS , SinopoulouV , AkobengA . Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource. World Journal of Gastroenterology2021;27:7572.">Gordon 2021b</a>). </p> <p>Safety will always be a real priority but may need other design types and, in turn, other designs of synthesis, such as those using large cohort observational studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012623-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012623-sec-0008"></div> <div class="table" id="CD012623-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Infliximab 5–10 mg/kg compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Amsterdam, Belgium, the Netherlands, UK, USA)<br/><b>Intervention:</b> infliximab <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> <p>defined as CDAI &lt; 150 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>546 per 1000<br/>(184 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.55</b><br/>(1.53 to 13.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> </p> <p>defined as improvement in the scores on the CDAI score ≥ 70 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>654 per 1000 (260 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.09</b> (1.63 to 10.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and one level due to serious concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Infliximab 5–10 mg/kg compared to placebo for exclusively fistulating population</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to placebo for exclusively fistulating population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> not reported (multiple countries)<br/><b>Intervention:</b> infliximab (combined 5 and 10 mg/kg dosages)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460 per 1000</p> <p>(178 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.57</b> (1.38 to 9.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>388 per 1000</p> <p>(220 to 682)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.94</b> (1.10 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.5 per 1000</p> <p>(0 to 152)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.50</b> (0.12 to 50.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to very serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Infliximab 5 mg/kg and purine analogues compared to purine analogues alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab and purine analogues compared to purine analogues alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Austria, Belgium, Canada, China, Denmark, France, Germany, Greece, Israel, Mexico, the Netherlands, Norway, Spain, Sweden, UK, USA)<br/><b>Intervention:</b> infliximab and purine analogues<br/><b>Comparison:</b> purine analogues </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with purine analogues</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with infliximab and purine analogues</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> as defined by the studies at weeks 24–26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>604 per 1000 (499 to 728)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.92</b> (1.59 to 2.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> as defined by the studies at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000 (486 to 760)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.64</b> (1.31 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000 (129 to 248)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.63 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>603</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting.<br/><sup>b</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision from low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Infliximab 5 mg/kg compared to purine analogues</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to purine analogues</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease<br/><b>Setting:</b> hospitals and tertiary centres (Belgium, Canada, China, Denmark, Sweden, USA)<br/><b>Intervention:</b> infliximab <br/><b>Comparison:</b> purine analogues </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with purine analogues</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000 (368 to 624)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (1.15 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000 (432 to 695)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b> (1.13 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>241 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000 (111 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> (0.46 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision from low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 10 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab 5 mg/kg compared to infliximab 10 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Belgium, England, Germany, the Netherlands, USA)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> infliximab 10 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 10 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 5 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as CDAI &lt; 150 at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>703 per 1000 (417 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> (1.06 to 3.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined as reduction in CDAI by 70 points at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>815 per 1000</p> <p>(540 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.63</b> (1.08 to 2.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and two levels due to concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 10 mg/kg for exclusively fistulating population</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab 5 mg/kg compared to infliximab 10 mg/kg for exclusively fistulating population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> not reported (multiple countries)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> infliximab 10 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 10 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 5 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median length of time of 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>548 per 1000</p> <p>(315 to 949)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> (0.84 to 2.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>563 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>675 per 1000 (462 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.82 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> <p>(2 to 505)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> (0.07 to 15.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 20 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Infliximab 5 mg/kg compared to infliximab 20 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Belgium, England, Germany, the Netherlands, USA)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> infliximab 20 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with infliximab 20 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with infliximab 5 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>703 per 1000</p> <p>(417 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> </p> <p>(1.06 to 3.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> as defined by the studies week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000 (540 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> (0.91 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and two levels due to very serious concerns with imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Infliximab 10 mg/kg compared to infliximab 20 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab 10 mg/kg compared to infliximab 20 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Belgium, England, Germany, the Netherlands, USA)<br/><b>Intervention:</b> infliximab 10 mg/kg<br/><b>Comparison:</b> infliximab 20 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 20 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 10 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as CDAI &lt; 150 at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> <p>(204 to 755)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.52 to 1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined by reduction of CDAI score by ≥ 70 at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>501 per 1000</p> <p>(315 to 791)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> </p> <p>(0.49 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and two levels due to very serious concerns with imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012623-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Infliximab 5 mg/kg compared to CT‐P13 biosimilar 5 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to biosimilar</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> 58 centres in 16 countries (Belgium, Brazil, Denmark, France, Germany, Hungary, Italy, Israel, Mexico, the Netherlands, Poland, Republic of Korea, Romania, Russia, Ukraine, USA)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> CT‐P13 biosimilar 5 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with CT‐P13 biosimilar</p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as CDAI &lt; 150 at week 6 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> <p>(317 to 582)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> (0.72 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined by reduction of CDAI score by ≥ 100 at week 6 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>631 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>612 per 1000</p> <p>(498 to 757)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> (0.79 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000</p> <p>(107 to 344)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> (0.70 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to very serious concerns with imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012623-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012623-sec-0009"></div> <section id="CD012623-sec-0010"> <h3 class="title" id="CD012623-sec-0010">Description of the condition</h3> <p>Crohn's disease (CD) is a chronic idiopathic disease characterised by transmural inflammation of the gastrointestinal tract (<a href="./references#CD012623-bbs2-0085" title="NeurathMF . Cytokines in inflammatory bowel disease. Nature Reviews Immunology2012;14(5):329-42.">Neurath 2012</a>). Although symptoms can vary, people with CD commonly present with abdominal pain, diarrhoea and weight loss. CD is not limited to the intestines. Between 25% and 70% of people with CD experience extraintestinal manifestations such as arthritis, osteoporosis, uveitis, erythema nodosum, psoriasis, ankylosing spondylitis, sacroiliitis, oral aphthous stomatitis, pyoderma gangrenosum and primary sclerosing cholangitis (<a href="./references#CD012623-bbs2-0087" title="Peyrin-BirouletL , vanAsscheG , Gómez-UlloaD , García-ÁlvarezL , LaraN , BlackC , et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clinical Gastroenterology and Hepatology2017;15(1):25-36.e27.">Peyrin‐Biroulet 2017</a>). While CD may present at any age, the peak ages of diagnosis are in the second and third decades of life (<a href="./references#CD012623-bbs2-0096" title="VindI , RiisL , JessT , KnudsenE , PedersenN , ElkjaerM , et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. American Journal of Gastroenterology2006;101(6):1274-82.">Vind 2006</a>). Fistulising Crohn's is a more severe form of the disease. </p> <p>In North America, the annual incidence of CD ranges from 3.1 to 14.6 cases per 100,000 person‐years, with a prevalence between 26 and 199 cases per 100,000 people (<a href="./references#CD012623-bbs2-0083" title="Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology2004;126(6):1504-17.">Loftus 2004</a>). The most recent estimates of the prevalence of inflammatory bowel disease (IBD) in the UK are 9 to 144/100,000 for CD (<a href="./references#CD012623-bbs2-0079" title="JonesGR , LyonsM , PlevrisN , JenkinsonPW , BissetC , BurgessC , et al. IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. Gut2019;68:1953-60.">Jones 2019</a>). </p> <p>Although the precise aetiology of CD remains unknown, it is believed that a genetic predisposition combined with exogenous (intestinal flora) and endogenous (epithelial cell function and immune cell function) factors contribute to the development of inflammation in the intestinal mucosa (<a href="./references#CD012623-bbs2-0062" title="BaumgartDC , CardingSR . Inflammatory bowel disease: cause and immunobiology. Lancet2007;369:1627-40.">Baumgart 2007</a>). This dysregulated inflammatory response creates an imbalance between pro‐inflammatory and anti‐inflammatory mediators. Available CD therapies attempt to attenuate the resulting inflammatory response (<a href="./references#CD012623-bbs2-0082" title="LichtensteinGR , SandbornWJ , RubinDT . The current and future use of anti-TNF alpha agents in Crohn's disease: is there an unmet need?Gastroenterology &amp; Hepatology2006;2(9):1-10.">Lichtenstein 2006</a>). </p> <p>Since CD is characterised by alternating states of active and quiescent disease, the therapeutic goal is to induce and maintain the remission of symptoms, as well as endoscopically and radiologically. Treatment guidelines recommend a sequential step‐up approach that focusses on treating the acute disease (i.e. inducing clinical remission) and maintaining response (<a href="./references#CD012623-bbs2-0081" title="LambCA , KennedyNA , RaineT , HendyPA , SmithPJ , LimdiJK , et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut2019;68(3):s1-106.">Lamb 2019</a>). At the bottom of the pyramid are treatments such as elimination diets, antibiotics and glucocorticoids, which may be less effective but are associated with limited systemic toxicity. In a step‐up manner, non‐responders are subsequently treated with more aggressive, potentially toxic medications including immunosuppressives (i.e. azathioprine, 6‐mercaptopurine and methotrexate) as well as biological drugs (i.e. infliximab, adalimumab, certolizumab, natalizumab, ustekinumab and vedolizumab) in an attempt to induce and maintain remission (<a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0074" title="HaC , KornbluthA . Vedolizumab as a treatment for Crohn's disease and ulcerative colitis. Gastroenterology &amp; Hepatology2014;10(12):793-800.">Ha 2014</a>; <a href="./references#CD012623-bbs2-0086" title="OkabayashiS , YamazakiH , YamamotoR , AnanK , MatsuokaK , KobayashiT , et al. Certolizumab pegol for maintenance of medically induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2022, Issue 6. Art. No: CD013747. [DOI: 10.1002/14651858.CD013747.pub2]">Okabayashi 2022</a>; <a href="./references#CD012623-bbs2-0089" title="RawlaP , SunkaraT , RajJP . Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. Journal of inflammation research2018;11:215.">Rawla 2018</a>). </p> <p>Conventional treatment options for people with active CD include systemic corticosteroids (e.g. hydrocortisone, prednisolone), locally acting corticosteroids (e.g. budesonide), and immunosuppressives (e.g. azathioprine, 6‐mercaptopurine and methotrexate). However, corticosteroid resistance develops in 16% to 20% of people with active CD (<a href="./references#CD012623-bbs2-0067" title="Faubion WA Jr, Loftus EV Jr, HarmsenWS , ZinsmeisterAR , SandbornWJ . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology2001;121(2):255-60.">Faubion 2001</a>; <a href="./references#CD012623-bbs2-0084" title="MunkholmP , LangholzE , DavidsenM , BinderV . Disease activity courses in a regional cohort of Crohn's disease patients. Scandinavian Journal of Gastroenterology1995;30(7):699-706.">Munkholm 1995</a>), and many people do not respond to immunosuppressives. </p> </section> <section id="CD012623-sec-0011"> <h3 class="title" id="CD012623-sec-0011">Description of the intervention</h3> <p>Infliximab is a human–mouse chimeric monoclonal antibody that works by binding and neutralising the pro‐inflammatory cytokine tumour necrosis factor‐alpha (TNF‐α), which is found in high levels in the blood serum, mucosa and stool of people with CD. Infliximab is able to render this cytokine biologically inactive (<a href="./references#CD012623-bbs2-0080" title="KnightDM , TrinhH , LeJ , SiegalS , ShealyD , McDonoughM , et al. Construction and initial characterisation of a mouse-human anti-TNF antibody. Molecular Immunology1993;30(16):1443-53.">Knight 1993</a>). </p> <p>Infliximab belongs in a category of drugs called biologicals. Biologicals are produced, either entirely or partly, from biological sources, and target the immune system's inflammatory responses. </p> </section> <section id="CD012623-sec-0012"> <h3 class="title" id="CD012623-sec-0012">How the intervention might work</h3> <p>Cytokines, which are intercellular mediators, control the inflammatory process in CD (<a href="./references#CD012623-bbs2-0093" title="SartorRB . Cytokines in intestinal inflammation: patho-physiological and clinical considerations. Gastroenterology1994;106(2):533-9.">Sartor 1994</a>). Chronic local inflammation occurs as a result of mucosal overproduction of pro‐inflammatory cytokines (<a href="./references#CD012623-bbs2-0091" title="RoglerG , AndusT . Cytokines in inflammatory bowel disease. World Journal of Surgery1998;22(4):383-9.">Rogler 1998</a>). One of several pro‐inflammatory mediators, TNF‐α, plays a key role in numerous inflammatory processes including CD, rheumatoid arthritis and other granulomatous diseases (<a href="./references#CD012623-bbs2-0063" title="BellS , KammMA . Anti-TNF-alpha antibody treatment for Crohn's disease. Research and Clinical Forums2000;22:129-35.">Bell 2000</a>). Drugs that inhibit the actions of TNF‐α, including infliximab, are termed TNF‐α antagonists. </p> <p>In people with CD, the local effects of infliximab on inflamed bowel mucosa lead to a reduction in TNF‐α‐expressing cells within four weeks of starting treatment. Compared to people treated with placebo, the colonic lamina propria of people treated with infliximab have demonstrated greater than 50% reduction of cells that produce TNF‐α including CD4+, CD8+, CD68+ monocytes and macrophages (<a href="./references#CD012623-bbs2-0060" title="BaertFJ , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22-8.">Baert 1999</a>). Treatment with infliximab also leads to a reduction in the number of interferon‐gamma‐ and TNF‐α‐producing mononuclear cells in the lamina propria of people with CD (<a href="./references#CD012623-bbs2-0088" title="PlevySE , LandersCJ , PrehnJ , CarramanzanaNM , DeemRL , ShealyD , et al. A role for TNF alpha mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. Journal of Immunology1997;159(12):6276-82.">Plevy 1997</a>). Infliximab reduces the expression of adhesion molecules (ICAM‐1 (intercellular adhesion molecule‐1) and LFA‐1 (lymphocyte function‐associated antigen‐1)) (<a href="./references#CD012623-bbs2-0060" title="BaertFJ , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22-8.">Baert 1999</a>). Along with histological repair, infliximab appears to be effective for achieving endoscopic healing, which is correlated with a reduction in disease activity as shown by <a href="./references#CD012623-bbs2-0065" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34.">D'Haens 1999</a>. </p> </section> <section id="CD012623-sec-0013"> <h3 class="title" id="CD012623-sec-0013">Why it is important to do this review</h3> <p>The discovery of infliximab was a turning point in the management of CD. Although biologicals can provide rapid and effective clinical response, mucosal healing, improved quality of life and reduced need for surgery, whether these drugs are a cost‐effective choice is debated (<a href="./references#CD012623-bbs2-0064" title="Cote-DaigneaultJ , BouinM , LahaieR , ColombelJF , PoitrasP . Biologics in inflammatory bowel disease: what are the data?United European Gastroenterology Journal2015;3(5):419-28.">Cote‐Daigenault 2015</a>). </p> <p>Infliximab is a promising therapeutic option for people with moderate‐to‐severe active CD who fail to respond to conventional therapy or have fistulising disease. The ACCENT‐I and ACCENT‐II trials suggest that infliximab is effective for inducing and maintaining remission (<a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0092" title="SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85.">Sands 2004a</a>). ACCENT‐I demonstrated that scheduled infliximab treatment may be more effective than sporadic treatment, and it can lead to a greater probability of mucosal healing and decreased hospital admissions (<a href="./references#CD012623-bbs2-0061" title="BaertF , MoortgatL , vanAsscheG , CaenepeelP , VergauweP , De VosM , et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology2010;138(2):463-8.">Baert 2010</a>). </p> <p>Although a previous Cochrane Review assessed the efficacy and safety of TNF‐α antagonists for induction of remission in CD (<a href="./references#CD012623-bbs2-0059" title="AkobengAK , ZachosM . Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD003574. [DOI: 10.1002/14651858.CD003574.pub2]">Akobeng 2003</a>), this review will focus on infliximab. It will provide an up‐to‐date summary of the benefits and harms of infliximab used for the treatment of moderate‐to‐severe CD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012623-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012623-sec-0014"></div> <p>To evaluate the benefits and harms of infliximab alone or in combination with another agent for induction of remission in Crohn's disease compared to placebo or active medical therapies. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012623-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012623-sec-0015"></div> <section id="CD012623-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012623-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all types of randomised controlled trials (RCT) for inclusion. Quasi‐randomised trials (using inappropriate randomisation methods) were ineligible. </p> </section> <section id="CD012623-sec-0018"> <h4 class="title">Types of participants</h4> <p>We considered adults aged greater than 18 years with active CD as defined by the study authors (as per conventional clinical, radiological or endoscopic criteria) for inclusion. Participants with all disease locations and behaviours as defined by the primary study. There were no restrictions applied for sex, disease duration or previous medication exposure. </p> <p>We included studies with CD as a subset of a wider IBD population only if they offered separate data for the participants with CD. We included studies reporting on CD subsets (e.g. fistulating population), and analysed them separately from the general CD populations. </p> </section> <section id="CD012623-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies analysing infliximab, alone or in combination with another agent, compared to placebo or active medical therapies for induction of remission in people with CD. </p> <p>In studies where purine analogue use exceeded 50% amongst all participants, we considered the purine analogues as part of the intervention. </p> <p>We excluded surgical interventions from this review.</p> </section> <section id="CD012623-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included both dichotomous and continuous outcomes.</p> <section id="CD012623-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012623-list-0001"> <li> <p><b>Clinical remission</b> (as defined by the included studies), as measured at the primary endpoint of the study, but not later than 26 weeks </p> </li> <li> <p><b>Clinical response</b> (as defined by the included studies), as measured at the primary endpoint of the study, but not later than 26 weeks </p> </li> <li> <p><b>Withdrawals due to adverse events</b> for the duration of the follow‐up </p> </li> </ul> </p> </section> <section id="CD012623-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012623-list-0002"> <li> <p><b>Endoscopic remission</b> (as defined by the included studies), as measured at the primary endpoint of the study, but not later than 26 weeks </p> </li> <li> <p><b>Histological remission</b> (as defined by the included studies), as measured at the primary endpoint of the study, but not later than 26 weeks </p> </li> <li> <p><b>Endoscopic response</b> (as defined by the included studies), as measured at the primary endpoint of the study, but not later than 26 weeks </p> </li> <li> <p><b>Serious adverse events</b> for the duration of the follow‐up of the included studies </p> </li> <li> <p><b>Total adverse events</b> for the duration of the follow‐up of the included studies </p> </li> </ul> </p> </section> </section> </section> <section id="CD012623-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012623-sec-0024"> <h4 class="title">Electronic searches</h4> <p>On 31 August 2021 and 4 March 2023, the Cochrane Gut Information Specialist searched the following sources. </p> <p> <ul id="CD012623-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library (Issue 2, 2023) </p> </li> <li> <p>MEDLINE via OvidSP (1946 to 2 March 2023)</p> </li> <li> <p>Embase via OvidSP (1974 to week 8 2023)</p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>; searched 4 March 2023) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>; searched 4 March 2023) </p> </li> </ul> </p> <p>We did not apply any date, language, document type or publication status limitations to this search. For the search strategies, see <a href="./appendices#CD012623-sec-0156">Appendix 1</a>. </p> </section> <section id="CD012623-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the references of included studies and applicable systematic reviews to identify additional studies. We searched conference proceedings from Digestive Disease Week, the European Crohn's and Colitis Organisation Congress and United European Gastroenterology Week to identify studies reported in abstract form only for the last 24 months to cover for possible indexing delays between the publication of conference abstracts and their indexing in Embase. </p> <p>We also corresponded with authors and experts in the field to identify unpublished data. </p> </section> </section> <section id="CD012623-sec-0026"> <h3 class="title" id="CD012623-sec-0026">Data collection and analysis</h3> <section id="CD012623-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Four review authors (GWM, SJR, ME, AMD) worked in pairs to assess publications identified by the search strategy to determine eligibility based on the above inclusion criteria. We resolved any disagreements by discussion and consensus amongst the review authors. If consensus could not be reached, we consulted a fifth review author (MG). </p> </section> <section id="CD012623-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We collected information from included studies using a standardised data collection form. Pairs of review authors independently extracted data. We resolved disagreements by discussion and consensus. If consensus could not be reached, we consulted a fifth review author (MG). </p> <p>The extracted data included the following.</p> <p> <ul id="CD012623-list-0004"> <li> <p>General information (title, journal, year, publication type)</p> </li> <li> <p>Study information (design, methods of randomisation, concealment of allocation and blinding, power calculation, a priori and post hoc analyses) </p> </li> <li> <p>Intervention and control (type and dose of medication; placebo or active comparator)</p> </li> <li> <p>Eligibility (total number of participants screened and randomised)</p> </li> <li> <p>Baseline characteristics for each arm (age, sex, ethnicity, disease severity, concurrent medications, prior medications) </p> </li> <li> <p>Follow‐up (length of follow‐up, assessment of treatment compliance, withdrawals, number of participants lost to follow‐up) </p> </li> <li> <p>Outcomes (primary and secondary outcomes)</p> </li> </ul> </p> </section> <section id="CD012623-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (GWM, SJR, ME, AMD) worked in pairs to assess the risk of bias of each included study using the Cochrane RoB 1 tool (<a href="./references#CD012623-bbs2-0075" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We assessed the following factors. </p> <p> <ul id="CD012623-list-0005"> <li> <p>Random sequence generation (i.e. randomisation method)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (i.e. methods used by investigators to deal with attrition)</p> </li> <li> <p>Selective reporting (i.e. investigators reported all outcomes)</p> </li> <li> <p>Other bias (i.e. any other factor that could have increased bias)</p> </li> </ul> </p> <p>We judged studies at high, low or unclear risk of bias. We resolved disagreements by consensus via discussion. If consensus could not be reached, we consulted a fifth review author (MG). </p> </section> <section id="CD012623-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed all data on an intention‐to‐treat (ITT) basis using Review Manager Web (<a href="./references#CD012623-bbs2-0090" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). </p> <p>For dichotomous outcomes, we expressed the treatment effect as risk ratios (RR) with corresponding 95% confidence intervals (CI). For continuous outcomes, we expressed the treatment effect as mean differences (MD) with 95% CIs when studies used the same scale. When studies used different scales to measure the same underlying construct, we calculated the standardised mean difference (SMD) and 95% CI. </p> <p>As the included studies differed in their chosen primary outcome data time points, we included different time points in our meta‐analyses, which we then investigated for heterogeneity (<a href="#CD012623-sec-0033">Assessment of heterogeneity</a>). We extracted no further time‐to‐event data. </p> </section> <section id="CD012623-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. For studies comparing more than two intervention groups, we made multiple pairwise comparisons between all possible pairs of intervention groups. To avoid double counting, we divided shared intervention groups evenly amongst the comparisons. For dichotomous outcomes, we divided both the number of events and the total number of participants. For continuous outcomes, we only divided the total number of participants, and left the means and standard deviations unchanged. </p> <p>We included cross‐over studies, but only pooled their data if they were reported separately before and after cross‐over, and we only used pre‐cross‐over data. </p> </section> <section id="CD012623-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We based our analysis on the data made available by the study authors. We contacted study authors to request missing data, data that were not reported in sufficient detail or unclear data. </p> <p>For efficacy outcomes, we used the numbers randomised as denominators. For numerators, we used the numbers as reported by the study authors. Participants with missing or unclear data were assumed to be treatment failures. </p> <p>For safety outcomes, we considered participants with missing or unclear withdrawal data as withdrawals due to adverse events. The denominators used for this outcome were as reported by the study authors. For serious and total adverse events, we used the numbers of events per participant, as reported by the study authors. We discarded outcome data reported for mixes of randomised and non‐randomised participants. </p> <p>We employed the same methods in our sensitivity analyses.</p> </section> <section id="CD012623-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We scrutinised studies to ensure that they were clinically homogeneous in terms of participants, interventions, comparators and outcomes. To test for statistical heterogeneity, we used a Chi² test. A P value of less than 0.1 gave an indication of the presence of heterogeneity. We quantified inconsistency using the I² statistic. We interpreted the thresholds as follows (<a href="./references#CD012623-bbs2-0076" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>). </p> <p> <ul id="CD012623-list-0006"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%; may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>We examined possible explanations for heterogeneity when there were sufficient data available, including factors such as participant characteristics (e.g. age, sex), condition severity, healthcare system and country. We did not pool data in a meta‐analysis if there was a considerable degree of statistical heterogeneity (I² greater than 75%). In the case of considerable statistical heterogeneity, we investigated whether this could be explained on clinical grounds or risk of bias, in which case, we aimed to conduct sensitivity analyses. If we found no reasons for the considerable statistical heterogeneity, we presented the results narratively, in detail. </p> </section> <section id="CD012623-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Our use of an inclusive search strategy minimised most reporting biases. We aimed to investigate publication bias using a funnel plot for outcomes with 10 or more studies and determine the magnitude of publication bias by visual inspection of the asymmetry of the funnel plot or other methods mentioned in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012623-bbs2-0076" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>). We would also have tested funnel plot asymmetry by performing a linear regression of the intervention effect estimate against its standard error, weighted by the inverse of the variance of the intervention effect estimate (<a href="./references#CD012623-bbs2-0066" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). </p> </section> <section id="CD012623-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We combined data from individual trials for meta‐analysis when the interventions, participant groups and outcomes were sufficiently similar (as determined by consensus). For dichotomous outcomes, we calculated the pooled RR and 95% CI. For continuous outcomes, we calculated the pooled MD and corresponding 95% CI when studies used the same scale. When studies used different scales to measure the same underlying construct, we calculated the SMD and 95% CI. We used a random‐effects model to pool data. If there was a high degree of heterogeneity (I<sup>2</sup> of 75 or greater), we did not pool data for meta‐analysis. </p> <p>We reported data that could not be meta‐analysed in narrative form using the <a href="https://training.cochrane.org/resource/synthesis-without-meta-analysis-swim-reporting-guideline" target="_blank">SWiM guidance</a>. </p> </section> <section id="CD012623-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Planned subgroup analyses were:</p> <p> <ul id="CD012623-list-0007"> <li> <p>different drug doses and dosing frequencies;</p> </li> <li> <p>concomitant immunosuppressant medication use and</p> </li> <li> <p>different disease behaviours.</p> </li> </ul> </p> <p>If heterogeneity was detected, we investigated possible causes, and addressed them using methods described in <a href="./references#CD012623-bbs2-0076" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>. </p> </section> <section id="CD012623-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Planned sensitivity analyses to examine the impact of the following variables on the pooled effect were: </p> <p> <ul id="CD012623-list-0008"> <li> <p>random‐effects versus fixed‐effect modelling;</p> </li> <li> <p>low risk of bias versus unclear or high risk of bias;</p> </li> <li> <p>relevant loss to follow‐up (greater than 10%): best‐case versus worst‐case scenario;</p> </li> <li> <p>full‐text manuscript versus abstract or unpublished studies.</p> </li> </ul> </p> </section> <section id="CD012623-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented a summary of our findings and GRADE decisions for all comparisons for all three of our primary outcomes in the summary of findings tables. </p> <p>We assessed the overall certainty of the evidence for the primary and secondary outcomes using the GRADE approach (<a href="./references#CD012623-bbs2-0073" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>; <a href="./references#CD012623-bbs2-0094" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Schünemann 2011</a>). Evidence retrieved from RCTs is usually regarded as high certainty. However, the certainty rating may be downgraded as a result of: </p> <p> <ul id="CD012623-list-0009"> <li> <p>risk of bias;</p> </li> <li> <p>indirect evidence;</p> </li> <li> <p>inconsistency (unexplained heterogeneity);</p> </li> <li> <p>imprecision and</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <section id="CD012623-sec-0039"> <h5 class="title">GRADE Working Group grades of evidence</h5> <p> <ul id="CD012623-list-0010"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012623-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012623-sec-0040"></div> <section id="CD012623-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD012623-sec-0042"> <h4 class="title">Results of the search</h4> <p>Our search, conducted up to March 2023, identified 7066 records. After removing duplicates, 7055 records underwent title and abstract screening to assess eligibility, of which we excluded 6982 records. The remaining 73 records underwent full‐text review, of which we excluded 48 records (47 studies) with reasons, and found one ongoing study (one record). </p> <p>We included 10 RCTs with 1101 randomised participants.</p> <p>The results of the search are presented in the study flow diagram (<a href="#CD012623-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012623-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012623-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012623-sec-0043"> <h4 class="title">Included studies</h4> <p>A summary of key characteristics and interventions across the included studies is shown in <a href="#CD012623-tbl-0010">Table 1</a> and <a href="#CD012623-tbl-0011">Table 2</a>. The outcome data can be found in <a href="#CD012623-tbl-0012">Table 3</a>. See also the <a href="./references#CD012623-sec-0171" title="">Characteristics of included studies</a> table. </p> <div class="table" id="CD012623-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies' characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Numbers randomised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Purine analogues use</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Biological naive or not</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> combination therapy </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 508</p> <p><b>IG1:</b> 169 </p> <p><b>IG2:</b> 169 </p> <p><b>CG:</b> 170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg </p> <p><b>IG2:</b> IFX 10 mg </p> <p><b>IG3:</b> IFX 20 mg </p> <p><b>CG:</b> placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 30</p> <p><b>IG1:</b> 7 </p> <p><b>IG2:</b> 7 </p> <p><b>IG3:</b> 8 </p> <p><b>CG:</b> 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concomitant azathioprine</p> <p><b>IG1:</b> 3/7 </p> <p><b>IG2:</b> 1/7 </p> <p><b>IG3:</b> 5/8 </p> <p><b>CG:</b> 3/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg + AZA 2–2.5 mg/kg </p> <p><b>CG:</b> corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 133</p> <p><b>IG1:</b> 67 </p> <p><b>CG:</b> 66 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> AZA 2.5 mg/kg + IFX 5 mg/kg </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 24</p> <p><b>IG1:</b> 8 </p> <p><b>IG2:</b> 8 </p> <p><b>CG:</b> 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX infusion, regimen 1 </p> <p><b>IG2:</b> IFX infusion, regimen 2 </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 238</p> <p><b>IG1:</b> 79 </p> <p><b>IG2:</b> 81 </p> <p><b>CG:</b> 78 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only reported for the whole cohort (238 participants)</p> <p>5‐ASA: 288</p> <p>AZA/6‐MP: 63</p> <p>Methotrexate: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 115</p> <p><b>IG:</b> 57 </p> <p><b>CG:</b> 58 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> IFX 10 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 94</p> <p><b>IG1:</b> 31 </p> <p><b>IG2:</b> 32 </p> <p><b>CG:</b> 31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine or azathioprine:</p> <p><b>IG1:</b> 12/31 </p> <p><b>IG2:</b> 17/32 </p> <p><b>CG:</b> 9/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 87</p> <p><b>IG:</b> 43 </p> <p><b>CG:</b> 44 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine or azathioprine:</p> <p>Overall: 53/87 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> cA2 at 5 mg/kg </p> <p><b>IG2:</b> cA2 at 10 mg/kg </p> <p><b>IG3:</b> cA2 at 20 mg/kg </p> <p><b>CG:</b> 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 108</p> <p><b>IG1:</b> 27 </p> <p><b>IG2:</b> 28 </p> <p><b>IG3:</b> 28 </p> <p><b>CG:</b> 25 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 4 </p> <p>Azathioprine:</p> <p><b>IG1:</b> 5 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 8 </p> <p><b>CG:</b> 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> CT‐P13 biosimilar 5 mg/kg </p> <p><b>CG:</b> IFX 5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number randomised: 220</p> <p><b>IG:</b> 111 </p> <p><b>CG:</b> 109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine or azathioprine:</p> <p><b>IG:</b> 84/111 </p> <p><b>CG:</b> 80/109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>5‐ASA: 5‐aminosalicylic acid; 6‐MP: 6‐mercaptopurine; AZA: azathioprine; cA2: early name for infliximab; IFX: infliximab; CG: control group; IG: intervention group. </p> </div> </div> <div class="table" id="CD012623-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Included studies' intervention details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention medications</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Previous experience of biological therapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Medications up to starting study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Medications that had to be discontinued prior to starting study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mandatory medications per study protocol</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant medications during study</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX only. IV infusion of IFX 5 mg/kg at weeks 0, 2, 6, 14 and 22, plus daily oral placebo capsules through 30 weeks </p> <p><b>IG2:</b> combination therapy. IV infusion of IFX 5 mg/kg at weeks 0, 2, 6, 14 and 22 plus daily oral AZA capsules 2.5 mg/kg through 30 weeks </p> <p><b>CG:</b> AZA only. Daily oral capsules 2.5 mg/kg through 30 weeks plus placebo IV infusion at weeks 0, 2, 6, 14 and 22 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> <p>All participants naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1</b> </p> <p>No steroids: 117</p> <p>Steroids &lt; 20 mg: 19</p> <p>Steroids &gt; 20 mg: 33</p> <p>Budesonide: 28</p> <p>5‐ASA: 87</p> <p><b>IG2</b> </p> <p>No steroids: 122</p> <p>Steroids &lt; 20 mg: 14</p> <p>Steroids &gt; 20 mg: 33</p> <p>Budesonide: 19</p> <p>5‐ASA: 85</p> <p><b>CG</b> </p> <p>No steroids: 130</p> <p>Steroids &lt; 20 mg: 14</p> <p>Steroids &gt; 20 mg: 26</p> <p>Budesonide: 25</p> <p>5‐ASA: 104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic steroids</p> <p><b>IG1:</b> 60 </p> <p><b>IG2:</b> 58 </p> <p><b>CG:</b> 60 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> single IV dose IFX 5 mg/kg </p> <p><b>IG2:</b> single IV dose IFX 10 mg/kg </p> <p><b>IG3:</b> single IV dose IFX 20 mg/kg </p> <p><b>CG:</b> single IV dose of placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> <p><i>(exclusion criteria)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 3 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 5 </p> <p>AZA:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 3 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> single IV dose IFX 5 mg/kg at weeks 0, 2, 6 with AZA 2–2.5 mg/kg per day. </p> <p>If not tolerating AZA, 6‐MP given initial dose of 25 mg each week for 12 weeks with the dose reduced to 15 mg/week thereafter </p> <p><b>IG2:</b> corticosteroids then AZA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (exclusion criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (exclusion criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> AZA 50/65 (77%) </p> <p>MTX 16/65(25%)</p> <p><b>IG2:</b> AZA 38/64 (60%) </p> <p>MTX 8/64 (13%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IV IFX 5 mg/kg at weeks 0, 2 and 6 to induce remission followed by IFX 5 mg/kg every 8 weeks to maintain remission </p> <p><b>IG2:</b> AZA PO 2.5 mg/kg qd, and IV IFX 5 mg/kg at weeks 0, 2 and 6 to induce remission, followed by IFX 5 mg/kg every 8 weeks to maintain remission </p> <p><b>CG:</b> AZA PO 2.5 mg/kg qd </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At week 0, all eligible participants received IFX 5 mg/kg IV</p> <p><b>IG1:</b> IFX 5 mg/kg infusions at week 2, 6 and every 8 weeks thereafter until week 46 </p> <p><b>IG2:</b> IFX 10 mg/kg infusions at weeks 2, 6 and every 8 weeks thereafter until week 46 </p> <p><b>CG:</b> placebo infusions at weeks 2, 6 and every 8 weeks thereafter until week 46 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were excluded from the study if they had received previous treatment with IFX or any other agent targeted at TNF </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA: 129</p> <p>6‐MP and AZA: 63</p> <p>MTX: 13</p> <p>Corticosteroids of which:</p> <p>any – 118</p> <p>&gt; 20 mg/day: 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants not receiving medical therapy had to have discontinued treatment for ≥ 4 weeks before screening </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same as medications up to the start of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants were treated with AZA/6‐MP 2–3 mg/kg</p> <p> <ul id="CD012623-list-0011"> <li> <p>Failure stratum (56 enroled):</p> <ul id="CD012623-list-0012"> <li> <p><b>IG:</b> 26 IFX 0, 2 and 6 weeks at 5 mg/kg </p> </li> <li> <p><b>CG:</b> 29 placebo </p> </li> </ul> </li> <li> <p>Naive stratum (59 enroled):</p> <ul id="CD012623-list-0013"> <li> <p><b>IG:</b> 31 IFX 0, 2 and 6 weeks at 5 mg/kg </p> </li> <li> <p><b>CG:</b> 27 placebo </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(exclusion criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received steroids: 115</p> <p>All participants in the failure stratum were on and continued to use AZA:</p> <p>56/115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA, budesonide, artificial nutrition or other immunosuppressive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants were treated with AZA 2–3 mg/kg per day or 6‐MP 1.0–1.5 mg/kg per day. Participants previously treated with AZA or 6‐MP (failure stratum) continued their treatment at the same dose; in the naive‐stratum participants were treated with AZA 2.0–2.5 mg/kg per day, started 1 week after the first IFX infusion. The AZA or 6‐MP had to be maintained at a stable dose throughout the study, except for participants who experienced toxicity related to the drug. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg (0, 2 and 6 weeks) </p> <p><b>IG2:</b> IFX 10 mg/kg (0, 2 and 6 weeks) </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> (n = 31) </p> <p>Corticosteroids: 12<br/>6‐MP and AZA: 12<br/>5‐ASA: 17<br/>Antibiotics: 6 </p> <p><b>IG2:</b> (n = 32) </p> <p>Corticosteroids: 10 <br/>6‐MP and AZA: 17<br/>5‐ASA: 16<br/>Antibiotics: 11 </p> <p><b>CG:</b> (n = 31) </p> <p>Corticosteroids: 11<br/>6‐MP and AZA: 9<br/>5‐ASA: 19<br/>Antibiotics: 11 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclosporin (excluded from the start)</p> <p>IF not already on a stable dose of steroids/AZA/aminosalicylates/MTX medications had to have discontinued ≥ 4 weeks before enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1 + IG2:</b> </p> <p>Corticosteroids: 21<br/>6‐MP or AZA: 29<br/>5‐ASA: NR<br/>Antibiotics: 17 </p> <p>(the numbers were the same as medication up to study, so it seems most of the participants who were on these drugs continued throughout the study, although the paper did not state it) </p> <p><b>CG:</b> </p> <p>Corticosteroids: 11<br/>6‐MP or AZA: 9 <br/>5‐ASA: 19 <br/>Antibiotics: 11 </p> <p>Study reported IG1 and IG2, concomitant use</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg, IV, at weeks 14, 22, 30, 38 and 46. Beginning at week 22, participants who had a loss of response were eligible to cross over to maintenance treatment with IFX 10 mg/kg </p> <p><b>CG:</b> placebo (agent, dose and route: NR) at weeks 14, 22, 30, 38 and 46. Beginning at week 22, participants who had a loss of response were eligible to cross over to maintenance treatment with IFX 5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> single dose, IV, cA2 at 5 mg/kg </p> <p><b>IG2:</b> single dose, IV, cA2 at 10 mg/kg </p> <p><b>IG3:</b> single dose, IV, cA2 at 20 mg/kg </p> <p><b>CG:</b> single dose, IV, placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> <p><i>(exclusion criteria)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n per group (%)</p> <p>Prednisolone (&lt; 20 mg/day PO):</p> <p><b>IG1:</b> 8 </p> <p><b>IG2:</b> 8 </p> <p><b>IG3:</b> 10 </p> <p><b>CG:</b> 10 </p> <p>Prednisolone (≥ 20 mg/day PO):</p> <p><b>IG1:</b> 7 </p> <p><b>IG2:</b> 8 </p> <p><b>IG3:</b> 7 </p> <p><b>CG:</b> 6 </p> <p>6‐MP:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 4 </p> <p>AZA:</p> <p><b>IG1:</b> 5 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 8 </p> <p><b>CG:</b> 7 </p> <p>5‐ASA:</p> <p><b>IG1:</b> 16 </p> <p><b>IG2:</b> 18 </p> <p><b>IG3:</b> 13 </p> <p><b>CG:</b> 17 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No numbers reported.</p> <p>Participants who were receiving 5‐ASA, corticosteroids, AZA or 6‐MP before the study continued to receive a stable dose during the trial period. </p> <p>The dose of corticosteroids could be tapered beginning 8 weeks after the initiation of the study. </p> <p>Treatment with these drugs or with MTX or ciclosporin could not be initiated during the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> CT‐P13 biosimilar 5 mg/kg </p> <p><b>CG:</b> IFX 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 54 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> </p> <p> <ul id="CD012623-list-0014"> <li> <p>Steroids 7/111 (33%)</p> </li> <li> <p>AZA 84/111 (76%)</p> </li> </ul> </p> <p><b>CG:</b> </p> <p> <ul id="CD012623-list-0015"> <li> <p>Steroids 33/109 (30%)</p> </li> <li> <p>AZA 80/109 (73%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>5‐ASA: 5‐aminosalicylic acid; 6‐MP: 6‐mercaptopurine; AZA: azathioprine; cA2: early name for infliximab; CG: control group; CT‐P13: subcutaneous infliximab; IFX: infliximab; IG: intervention group; IV: intravenous; MTX: methotrexate; n: number; NR: not reported; PO: oral; qd: once daily; TNF: tumour necrosis factor. </p> </div> </div> <div class="table" id="CD012623-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Primary and secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Group interventions</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinical remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinical response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Withdrawals due to adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Endoscopic remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Histological remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Endoscopic response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> combination therapy </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By week 26 (used in analysis)</p> <p><b>IG1:</b> 81/169 </p> <p><b>IG2:</b> 102/169 </p> <p><b>CG:</b> 54/170 </p> <p>By week 50</p> <p><b>IG1:</b> 64/169 </p> <p><b>IG2:</b> 80/169 </p> <p><b>CG:</b> 41/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI 70 response (week 26)</p> <p><b>IG1:</b> 95/169 </p> <p><b>IG2:</b> 113/169 </p> <p><b>CG:</b> 71/170 </p> <p>CDAI 70 response (week 50)</p> <p><b>IG1:</b> 75/169 </p> <p><b>IG2:</b> 88/169 </p> <p><b>CG:</b> 56/170 </p> <p>CDAI 100 response (week 26) used in analysis</p> <p><b>IG1:</b> 92/169 </p> <p><b>IG2:</b> 105/169 </p> <p><b>CG:</b> 64/170 </p> <p>CDAI 100 response (week 50)</p> <p><b>IG1:</b> 70/169 </p> <p><b>IG2:</b> 85/169 </p> <p><b>CG:</b> 47/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At week 54</p> <p><b>IG1:</b> 29/169 </p> <p><b>IG2:</b> 37/169 </p> <p><b>CG:</b> 42/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mucosal healing (week 26)</p> <p><b>IG1:</b> 28/169 </p> <p><b>IG2:</b> 47/169 </p> <p><b>CG:</b> 18/170 </p> <p><i>Randomised participants not assessed with endoscopy were counted as failures</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At week 54</p> <p><b>IG1:</b> 39/169 </p> <p><b>IG2:</b> 27/169 </p> <p><b>CG:</b> 43/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Through week 30</p> <p><b>IG1:</b> 41/169 </p> <p><b>IG2:</b> 39/169 </p> <p><b>CG:</b> 63/170 </p> <p>Through week 50</p> <p><b>IG1:</b> 53/169 </p> <p><b>IG2:</b> 53/169 </p> <p><b>CG:</b> 69/170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg </p> <p><b>IG2:</b> IFX 10 mg </p> <p><b>IG3:</b> IFX 20 mg </p> <p><b>CG:</b> placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR as dichotomous</p> <p>CDAI mean at week 4</p> <p><b>IG1:</b> 122.8 (SEM 26.1) </p> <p><b>IG2:</b> 220.5 (SEM 63.4) </p> <p><b>IG3:</b> 161.9 (SEM 34.5) </p> <p><b>CG:</b> 261.3 (SEM 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR as dichotomous</p> <p>CDEIS mean at week 4</p> <p><b>IG1:</b> 6.4 (SEM 5.1) </p> <p><b>IG2:</b> 4.3 (SEM 5.4) </p> <p><b>IG3:</b> 5.2 (SEM 2.8) </p> <p><b>CG:</b> 7.5 (SEM 5.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> <p>(except for 1 infliximab‐treated participant with exclusive rectosigmoidal Crohn's disease developed a new rectal stricture at the site of earlier severe ulceration) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg + AZA 2–2.5 mg/kg </p> <p><b>CG:</b> corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 14</p> <p><b>IG:</b> 43/67 </p> <p><b>CG:</b> 21/66 </p> <p>(taken from graph)</p> <p>After this time, infliximab was given to the CG and therefore no further data reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG</b> 14/67 </p> <p><b>CG</b> 14/66 </p> <p>at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR (only assessed post‐hoc)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG</b> 20/67 </p> <p><b>CG</b> 19/66 </p> <p><i>Not known at end of trial – we assumed that these occurred at 26 weeks</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear – numbers not reported per participant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> AZA 2.5 mg/kg+ IFX 5 mg/kg </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission at week 26 – decrease in CDAI &lt; 70 points but a total CDAI score of &lt; 150 </p> <p><b>IG1:</b> 4/8 </p> <p><b>IG2:</b> 5/8 </p> <p><b>CG:</b> 3/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical efficacy at week 26 – decrease in CDAI ≥ 70 points or a decrease of ≥ 25% of the total CDAI score </p> <p><b>CG:</b> 2/8 </p> <p><b>IG1:</b> 2/8 </p> <p><b>IG2:</b> 2/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> 1/8 </p> <p><b>IG2:</b> 0/8 </p> <p><b>CG:</b> 1/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Fully healed"</p> <p><b>IG1:</b> 1/8 </p> <p><b>IG2:</b> 4/8 </p> <p><b>CG:</b> 3/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Basically healing"</p> <p><b>IG1:</b> 1/8 </p> <p><b>IG2:</b> 1/8 </p> <p><b>CG:</b> 1/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX infusion, regimen 1 </p> <p><b>IG2:</b> IFX infusion, regimen 2 </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 12</p> <p><b>IG:</b> 43/57 </p> <p><b>CG:</b> 22/58 </p> <p>Week 24 (primary)</p> <p><b>IG:</b> 32/57 </p> <p><b>CG:</b> 17/58 </p> <p>Week 52</p> <p><b>IG:</b> 23/57 </p> <p><b>CG:</b> 13/58 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 2/57 </p> <p><b>CG:</b> 5/58 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDEIS Decrease from baseline (median):</p> <p>Week 24:</p> <p><b>IG:</b> 6.9 (IQR 4.1 to 9.5) </p> <p><b>CG:</b> 1.2 (IQR −1.5 to 4.4) </p> <p>Dichotomous outcome only reported for a subset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 3/57 </p> <p><b>CG:</b> 3/58 </p> <p>Table 2 described "Serious adverse event in 5 cases (infliximab, n = 3; placebo, n = 3)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 29/57 </p> <p><b>CG:</b> 28/58 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> IFX 10 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete response (defined as the absence of any draining fistulas at 2 consecutive visit) </p> <p><b>IG1:</b> 17/31 </p> <p><b>IG2:</b> 12/32 </p> <p><b>CG:</b> 4/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A reduction of ≥ 50% from baseline in the number of draining fistulas observed at ≥ 2 consecutive study visits </p> <p><b>IG1:</b> 21/31 </p> <p><b>IG2:</b> 18/32 </p> <p><b>CG:</b> 8/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> 1 </p> <p><b>IG2:</b> 1 </p> <p><b>CG:</b> 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 in total</p> <p><b>IG1:</b> 1/31 </p> <p><b>IG2:</b> 4/32 </p> <p><b>CG:</b> 0/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> 10/31 </p> <p><b>IG2:</b> 26/32 </p> <p><b>CG:</b> 12/31 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 9/43 </p> <p><b>CG:</b> 7/44 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> cA2 at 5 mg/kg </p> <p><b>IG2:</b> cA2 at 10 mg/kg </p> <p><b>IG3:</b> cA2 at 20 mg/kg </p> <p><b>CG:</b> 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &lt; 150 at week 4 (primary)</p> <p><b>IG1:</b> 19/27 </p> <p><b>IG2:</b> 11/28 </p> <p><b>IG3:</b> 11/28 </p> <p><b>CG:</b> 2/25 </p> <p>CDAI &lt; 150 at week 2</p> <p><b>IG1:</b> 16/27 </p> <p><b>IG2:</b> 10/28 </p> <p><b>IG3:</b> 10/28 </p> <p><b>CG:</b> 2/25 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 70‐point decrease clinical response at week 4</p> <p><b>IG1:</b> 22/27 </p> <p><b>IG2:</b> 14/28 </p> <p><b>IG3:</b> 18/28 </p> <p><b>CG:</b> 4/25 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> CT‐P13 biosimilar 5 mg/kg </p> <p><b>CG:</b> IFX 5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission at weeks 6, 14, and 30</p> <p>Week 6 (primary)</p> <p><b>IG:</b> 47 </p> <p><b>CG:</b> 49 </p> <p>Week 14</p> <p><b>IG:</b> 59 </p> <p><b>CG:</b> 60 </p> <p>Week 30</p> <p><b>IG:</b> 61 </p> <p><b>CG:</b> 62 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 6</p> <p>CDAI‐70</p> <p><b>IG:</b> 77 </p> <p><b>CG:</b> 81 </p> <p>CDAI‐100</p> <p><b>IG:</b> 67 </p> <p><b>CG:</b> 70 </p> <p>Week 14</p> <p>CDAI‐70</p> <p><b>IG:</b> 96 </p> <p><b>CG:</b> 96 </p> <p>CDAI‐100</p> <p><b>IG:</b> 78 </p> <p><b>CG:</b> 83 </p> <p>Week 30</p> <p>CDAI‐70</p> <p><b>IG:</b> 85 </p> <p><b>CG:</b> 82 </p> <p>CDAI‐100</p> <p><b>IG:</b> 80 </p> <p><b>CG:</b> 80 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Up to 30 weeks</i> </p> <p><b>IG:</b> 17/111 </p> <p><b>CG:</b> 21/109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 30 weeks</p> <p><b>IG:</b> 6/111 </p> <p><b>CG:</b> 9/109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 30 weeks</p> <p><b>IG:</b> 63/111 </p> <p><b>CG:</b> 70/109 </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AZA: azathioprine; cA2: early name for infliximab; CDAI: Crohn's Disease Activity Index; CDEIS: Crohn's Disease Endoscopic Index of Severity; CG: control group; IFX: infliximab; IG: intervention group; IQR: interquartile range; NR: not reported; SEM: standard error of the mean. </p> </div> </div> <section id="CD012623-sec-0044"> <h5 class="title">Study design</h5> <p>Nine were large RCTs conducted across multicentre hospitals in Europe (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). One was a single‐centre RCT conducted in China (<a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>). <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> was a cross‐over trial with cross‐over at week 30. </p> </section> <section id="CD012623-sec-0045"> <h5 class="title">Interventions</h5> <p> <ul id="CD012623-list-0016"> <li> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>: azathioprine 2.5 mg/kg compared to infliximab infusions of 5 mg/kg compared to combination oral azathioprine 2.5 mg/kg and infliximab infusions of 5 mg/kg (three arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>: infusions of placebo compared to infliximab infusions of 5 mg/kg compared to infliximab infusions of 10 mg/kg compared to infliximab infusions of 20 mg/kg (four arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>: corticosteroids compared to infusions of infliximab 5 mg/kg and azathioprine (two arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>: azathioprine compared to infusions of infliximab 5 mg/kg compared to azathioprine and infusions of infliximab 5 mg/kg (three arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>: placebo infusions compared to infusions of infliximab 5 mg/kg compared to infusions of infliximab 10 mg/kg (three arms). Only the non‐responders part of this trial was relevant for this review, as the responders were randomised separately for a maintenance trial. </p> </li> <li> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>: azathioprine compared to azathioprine and infusions of infliximab 5 mg/kg (two arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>: placebo infusions compared to infliximab infusions of 5 mg/kg compared to infliximab infusions of 10 mg/kg (three arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>: placebo compared to infliximab infusions of 5 mg/kg (two arms). Only the non‐responders part of this trial is relevant for this review, as the responders were randomised separately for a maintenance trial. </p> </li> <li> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>: infusions of placebo compared to infliximab infusions of 5 mg/kg compared to infliximab infusions of 10 mg/kg compared to infliximab infusions of 20 mg/kg (four arms) </p> </li> <li> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>: infliximab infusions of 5 mg/kg compared to CT‐P13 biosimilar infusions of 5 mg/kg (two pre‐cross‐over arms) </p> </li> </ul> </p> </section> <section id="CD012623-sec-0046"> <h5 class="title">Concurrent therapies</h5> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> allowed participants to use systemic steroids and <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> allowed participants the use of azathioprine and methotrexate. <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> allowed participants to receive corticosteroids, purine analogues, aminosalicylates and antibiotics. </p> <p>For <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>, participants who were receiving mesalamine, corticosteroids, azathioprine or mercaptopurine before the study continued to receive a stable dose during the trial. Treatment with these drugs or with methotrexate or ciclosporin could not be initiated during the trial. </p> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> allowed the continued use of 5‐aminosalicylates or antibiotics, corticosteroids, azathioprine and 6‐mercaptopurine, or methotrexate. </p> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> permitted 5‐aminosalicylates, oral corticosteroids, azathioprine, mercaptopurine, mycophenolate mofetil, methotrexate and antibiotics. </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>, <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>, <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>, and <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not mention the use of concurrent therapies in their studies. </p> </section> <section id="CD012623-sec-0047"> <h5 class="title">Disease activity</h5> <p>Eight studies reported disease activity at the beginning of the study, which was a Crohn's Disease Activity Index (CDAI) score between 220 and 400 (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). </p> <p>In <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>, disease activity was at least 150 on the CDAI scale. </p> <p>One study did not report disease activity at the beginning of the study (<a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>). </p> </section> <section id="CD012623-sec-0048"> <h5 class="title">Disease duration</h5> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> reported median disease duration for all included participants as 2.3 years. </p> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> reported median disease duration for the participants in the combined immunosuppression arm was two years and 2.5 years for those in the conventional management arm. </p> <p>In <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>, median disease duration was 37 (interquartile range 30–46) years for all non‐responder participants. </p> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> reported a disease duration between five and seven years for the treatment‐failure cohort, and three to four years for the treatment‐naive cohort. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported a disease duration for all participants of 11 to 13 years. </p> <p>In <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>, disease duration ranged between 0.3 and 49.8 years for all non‐responder participants. </p> <p>Four studies did not report disease duration (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). </p> </section> <section id="CD012623-sec-0049"> <h5 class="title">Location of disease</h5> <p>Ninety‐one participants had ileal disease, 274 ileocolonic disease and 161 colonic disease (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>). </p> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> reported findings from 26 participants with active perianal disease. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported findings from 53 participants who had undergone previous segmental resection. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> and <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> were performed with exclusively fistulating populations. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> and <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not report numbers of participants with fistulating disease. </p> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> did not report disease location. </p> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> reported disease location; however, it is unclear what proportion of the population was in which category due to the nature of the reporting. </p> </section> <section id="CD012623-sec-0050"> <h5 class="title">Age</h5> <p>All studies reported mean or median participant age, which was 26 to 65 years.</p> </section> <section id="CD012623-sec-0051"> <h5 class="title">Conflicts of interest</h5> <p>All studies except <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> declared conflicts of interest and funding from pharmaceutical companies. It is unclear whether <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> had conflicts or not as there were no related statements. The full declarations can be found in the <a href="./references#CD012623-sec-0171" title="">Characteristics of included studies</a> tables. </p> </section> </section> <section id="CD012623-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 47 studies (see <a href="./references#CD012623-sec-0172" title="">Characteristics of excluded studies</a> table). </p> <p> <ul id="CD012623-list-0017"> <li> <p>Twenty‐three for ineligible study design (<a href="./references#CD012623-bbs2-0011" title="BaimaJ , LimaT , MoreiraA , De BarrosK , DornaM , Da SilvaR , et al. Randomized clinical trial for clinical response evaluation in Crohn's disease: infliximab versus adalimumab. Inflammatory Bowel Diseases2016;22:S30. ">Baima 2016</a>; <a href="./references#CD012623-bbs2-0012" title="BernsteinCN , CohenRD . Infliximab as first-line therapy for severe Crohn's disease?Inflammatory Bowel Diseases2002;8(1):58-9. ">Bernstein 2002</a>; <a href="./references#CD012623-bbs2-0013" title="BernsteinCN , TennakoonA , Benchimol, TargonownikL , SinghH , ZubietaAA , et al. Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications. Journal of Crohn's and Colitis2020;14(10):1354-63. ">Bernstein 2020</a>; <a href="./references#CD012623-bbs2-0014" title="BillietT , CleynenI , BalletV , FerranteM , vanAsscheG , GilsA , et al. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. Alimentary Pharmacology &amp; Therapeutics2016;44(7):673-83. ">Billiet 2016</a>; <a href="./references#CD012623-bbs2-0015" title="BleslA , BinderL , WenzlH , HogenauerC , BorenichA , PregartnerG . Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Alimentary Pharmacology &amp; Therapeutics2021;54(5):667-77. ">Blesl 2021</a>; <a href="./references#CD012623-bbs2-0017" title="BodiniG , GianniEG , SavarinoV , Del Nero l, LoPlumoS , BrunacciM , et al. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. Digestive and Liver Disease2018;50(5):452-6. ">Bodini 2018</a>; <a href="./references#CD012623-bbs2-0018" title="BortlikM , DuricovaD , MalickovaK , MachkovaN , Bouzkova Ez, HrdlickaL , et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. Journal of Crohn's and Colitis2013;7(9):736-43. ">Bortlik 2013</a>; <a href="./references#CD012623-bbs2-0021" title="BuhlS , Dorn-RasmussenM , BrynskovJ , AinsworthMA , BendtzenK , KlausenPH , et al. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scandinavian Journal of Gastroenterology2020;55(8):884-90. ">Buhl 2020</a>; <a href="./references#CD012623-bbs2-0022" title="ChaparroM , GuerraI , IborraM , CabriadaJL , BujandaL , TaxoneraC , et al. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology2020;32:588-96. ">Chaparro 2020</a>; <a href="./references#CD012623-bbs2-0023" title="ColombelJF , AdedokunO , OmoniyiJ , GasinkC , GaoLL , CornillieFJ , et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clinical Gastroenterology and Hepatology2019;17:1525-32.e1. ">Colombel 2019</a>; <a href="./references#CD012623-bbs2-0025" title="EUCTR2008-006484-36-IT. Multicenter comparative study between nutritional therapy alone and anti-TNF-alpha monoclonal antibody in inducing and maintaining remission in pediatric Crohn's disease: a randomized controlled trial – nutrition and biologics in Crohn's disease. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008-006484-36-IT (first received 24 April 2009). ">EUCTR2008‐006484‐36‐IT</a>; <a href="./references#CD012623-bbs2-0027" title="EUCTR2011-003038-14-NL. A randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2011-003038-14-NL (first received 31 May 2012). ">EUCTR2011‐003038‐14‐NL</a>; <a href="./references#CD012623-bbs2-0030" title="FuM , LiuH , ChenvS . Preliminary study on treatment of Crohn's disease with infliximab. Unknown2011:26-8. ">Fu 2011</a>; <a href="./references#CD012623-bbs2-0033" title="KhannaR , BresselerB , LevesqueB , ZouG , StittL , GreenbergGS , et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet2015;386:1825-34. ">Khanna 2015</a>; <a href="./references#CD012623-bbs2-0034" title="LichtensteinGR , BalaM , HanC , DeWoodyK , SchaibleT . Infliximab improves quality of life in patients with Crohn's disease. Inflammatory Bowel Diseases2002;8(4):237-43. ">Lichtenstein 2002</a>; <a href="./references#CD012623-bbs2-0038" title="NarulaN , WongE , SenguptaNK . Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic naive Crohn's disease. Clinical Gastroenterology and Hepatology2021;21:s1542-3565. ">Narula 2021</a>; <a href="./references#CD012623-bbs2-0040" title="NCT01442025. Study investigating tailored treatment with infliximab for active Crohn's disease. clinicaltrials.gov/study/NCT01442025 (first received 28 September 2011). ">NCT01442025</a>; <a href="./references#CD012623-bbs2-0046" title="SampleC , BaileyRJ , TodorukD , SadowskiD , GramlichL , MilanM , et al. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Canadian Journal of Gastroenterology2002;16(3):165-70. ">Sample 2002</a>; <a href="./references#CD012623-bbs2-0047" title="Sanchez-HernandezJG , RebolloN , Martin-SuarezA , CalvoMV , MunozF . A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. British Journal of Clinical Pharmacology2020;86(6):1165-75. ">Sanchez‐Hernandez 2020</a>; <a href="./references#CD012623-bbs2-0048" title="SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004c</a>; <a href="./references#CD012623-bbs2-0051" title="SyversenS , GollG , JørgensenK , SandangerO , SextonJ , OlsenI , et al. Therapeutic drug monitoring compared to standard treatment of patients starting infliximab: results from a multicenter randomized controlled trial of 400 patients. American College of Rheumatology2020;72(Suppl 10):abstract 2029. ">Syversen 2020a</a>; <a href="./references#CD012623-bbs2-0053" title="SyversenSW , GollGL , JørgensenKK , Sandanger Ø, SextonJ , OlsenIC , et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA2021;325(17):1744-54. ">Syversen 2021</a>; <a href="./references#CD012623-bbs2-0057" title="YangBL , ChenYG , GuYF , ChenHJ , SunGD , ZhuP , et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World Journal of Gastroenterology2015;21:2475-82. ">Yang 2015</a>) </p> </li> <li> <p>Six for ineligible study intervention (<a href="./references#CD012623-bbs2-0016" title="BlumensteinI , SteinJ , SchroderO . Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. European Journal of Gastroenterology and Hepatology2006;18(1):11-6. ">Blumenstein 2006</a>; <a href="./references#CD012623-bbs2-0028" title="EUCTR2021-000469-33-NL. Scientific medical research comparing the effectiveness of Infliximab by injection in the abdominal tissue (subcutaneous) monotherapy and infliximab subcutaneous injection with anti-inflammatory drugs in the treatment of moderate to severe chronic inflammatory bowel disease. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-000469-33-NL (first received 25 March 2021). ">EUCTR2021‐000469‐33‐NL</a>; <a href="./references#CD012623-bbs2-0029" title="FeaganBG , McDonaldJW , PanaccioneR , EnnsRA , BernsteinCN , PonichTP , et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology2014;146(3):681-8. ">Faegan 2014</a>; <a href="./references#CD012623-bbs2-0036" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease (CD). Gastroenterology2004;126:A54. MantzarisGJ , PolyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease. In: Digestive Disease Week conference; 2004 May 15-20; New Orleans (LA). 2004. ">Mantzaris 2004</a>; <a href="./references#CD012623-bbs2-0042" title="NCT04835506. The OPTIMIZE trial. clinicaltrials.gov/show/NCT04835506 (first received 8 April 2021). PapamichaelK , JairathV , ZouG , CohenB , RitterT , SandsB , et al. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open2022;12(4):e057656. ">NCT04835506</a>; <a href="./references#CD012623-bbs2-0044" title="RutgeertsP , D'HaensG , TarganS , VasiliauskasE , HanauerSB , PresentDH , et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology1999;117(4):761-9. ">Rutgeerts 1999</a>) </p> </li> <li> <p>Eighteen for ineligible study population (<a href="./references#CD012623-bbs2-0019" title="BossuytP , DreesenE , RimolaJ , DevuysereS , BrueckerY , VanslembrouckR , et al. Pharmacokinetic and pharmacodynamic evaluation of radiological healing in Crohn's disease patients treated with infliximab: a TAILORIX MRE substudy. Journal of Crohn's and Colitis2019;13:S231. ">Bossuyt 2019</a>; <a href="./references#CD012623-bbs2-0020" title="BossuytP , ClaeysS , D'HaensS , HoefkensE , StrubbeB , MarichalD . Ultraproactive therapeutic drug monitoring based on point-of-care testing of infliximab is not superior to reactive drug monitoring in patients with inflammatory bowel disease: 1 year results of a pragmatic clinical trial. United European Gastroenterology Journal2020;8(8 Suppl):32. ">Bossuyt 2021</a>; <a href="./references#CD012623-bbs2-0024" title="D'HaensGR , VermeireS , LambrechtG , BaertFJ , BossuytP , NachuryM , et al. Drug-level based dosing versus symptom-based dose adaptation in patients with Crohn's disease: a prospective, randomized multicenter study (TAILORIX). Gastroenterology2016;1:S143. ">D'Haens 2016</a>; <a href="./references#CD012623-bbs2-0026" title="EUCTR2010-018431-18-DE. A multicenter trial comparing REMICADE (infliximab) and placebo in the prevention of recurrence in Crohn's disease patients undergoing surgical resection who are at an increased risk of recurrence. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2010-018431-18-DE (first received 24 June 2010). ">EUCTR2010‐018431‐18‐DE</a>; <a href="./references#CD012623-bbs2-0031" title="HaoX , FengT , YangY , ShiY , JingR , LiuS , et al. Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial. BMJ Open2020;10:e038429. ">Hao 2020</a>; <a href="./references#CD012623-bbs2-0032" title="JorgensenK . Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative subgroup analyses in Crohn's disease and ulcerative colitis in the nor-switch extension trial. United European Gastroenterology Journal2019;5(8):1140-1. ">Jogensen 2019</a>; <a href="./references#CD012623-bbs2-0035" title="Luna-ChadidM , Pérez CalleJL , MendozaJL , VeraMI , BermejoAF , SánchezF , et al. Predictors of response to infliximab in patients with fistulizing Crohn's disease. Revista Espanola De Enfermedades Digestivas2003;96:379-84. ">Luna‐Chadid 2003</a>; <a href="./references#CD012623-bbs2-0037" title="MascherettiS , HampeJ , CroucherP , NikolausS , AndusT , SchubertS , et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics2002;12(7):509-15. ">Mascheretti 2002</a>; <a href="./references#CD012623-bbs2-0039" title="NCT00004941. Phase III randomized study of anti-tumor necrosis factor chimeric monoclonal antibody (cA2) for patients with enterocutaneous fistulae as a complication of Crohn's disease. clinicaltrials.gov/study/NCT00004941 (first posted 25 February 2000). ">NCT00004941</a>; <a href="./references#CD012623-bbs2-0041" title="NCT02883452. A phase I study to evaluate pharmacokinetics, efficacy and safety of CT-P13 subcutaneous in patients with active Crohn's disease and ulcerative colitis. clinicaltrials.gov/study/NCT02883452 (first received 30 August 2016). ">NCT02883452</a>; <a href="./references#CD012623-bbs2-0043" title="RuemmeleFM , LachauxA , CezardJP , MoraliA , MaurageC , GiniesJL , et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on-demand maintenance therapy. Inflammatory Bowel Diseases2009;15(3):388-94. ">Ruemmele 2009</a>; <a href="./references#CD012623-bbs2-0045" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LitchensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2005;63(3):433-42. ">Rutgeerts 2005</a>; <a href="./references#CD012623-bbs2-0049" title="SchroderO , BlumensteinI , SteinJ . Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. European Journal of Gastroenterology &amp; Hepatology2006;18(1):11-6. ">Schroder 2006</a>; <a href="./references#CD012623-bbs2-0050" title="SorrentinoD , PaviottiA , ZarifiD , GeraciM , AvelliniC , ZoliG , et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab – a pilot study. Digestive Diseases and Sciences2012;57(5):1341-8. ">Sorrentino 2012</a>; <a href="./references#CD012623-bbs2-0052" title="SyversenSW , GollG , JorgensenKK , OlsenIC , SandangerO , GehinJE , et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials2020;21(13):3734-4. ">Syversen 2020b</a>; <a href="./references#CD012623-bbs2-0054" title="SzymanskaE , DadalskiM , SymanskaS , GrajowskaW , PronickiM , KierkusJ . The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease. Przegląd Gastroenterologiczny2016;11(3):176-80. ">Szymanska 2016</a>; <a href="./references#CD012623-bbs2-0055" title="TajiriH , MotoyaS , KinjoF , MaemotoA , MatsumotoT , SatoN , et al. Infliximab for pediatric patients with Crohn's disease: phase 3, open-label, uncontrolled, multicenter trial in Japan. PLOS One2018;13(8):e0201956. ">Tajiri 2018</a>; <a href="./references#CD012623-bbs2-0056" title="YamamotoT , UmegaeS , MatsumotoK . Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflammatory Bowel Disease2009;15(10):1460-6. ">Yamamoto 2009</a>) </p> </li> </ul> </p> </section> <section id="CD012623-sec-0053"> <h4 class="title">Studies awaiting classification</h4> <p>No studies are awaiting classification.</p> </section> <section id="CD012623-sec-0054"> <h4 class="title">Ongoing studies</h4> <p>One study is ongoing (<a href="./references#CD012623-bbs2-0058" title="KCT0007470. Efficacy and safety of formulation switching between infliximab SC and IV in patients with Crohn's disease (CHAMELEON Study). trialsearch.who.int/Trial2.aspx?TrialID=KCT0007470 (first received 30 June 2022). ">KCT0007470</a>; see <a href="./references#CD012623-sec-0173" title="">Characteristics of ongoing studies</a> table). </p> </section> </section> <section id="CD012623-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias assessment is displayed in <a href="#CD012623-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012623-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012623-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012623-sec-0056"> <h4 class="title">Allocation</h4> <p>Seven studies provided sufficient information about randomisation to judge them at low risk (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). </p> <p>Three studies did not describe the randomisation method and so were judged at unclear risk (<a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>). </p> <p>Nine studies provided adequate description of allocation concealment and were judged at low risk (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>) </p> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> was judged at unclear risk due to not providing sufficient information for judgement. </p> </section> <section id="CD012623-sec-0057"> <h4 class="title">Blinding</h4> <p>Eight studies were blinded and judged at low risk of performance bias (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> was at high risk as it was an open‐label study. <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not provide any information and was judged at unclear risk. </p> <p>Six studies were blinded and judged at low risk for outcome assessment (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). Four studies were judged at unclear risk due to lack of information (<a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>) </p> </section> <section id="CD012623-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Nine studies were at low risk for attrition bias (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). </p> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> was at unclear risk. </p> </section> <section id="CD012623-sec-0059"> <h4 class="title">Selective reporting</h4> <p>Three studies were at low risk for selective reporting bias (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>), and another five at unclear risk (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>). </p> <p>Two studies were at high risk (<a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>). </p> </section> <section id="CD012623-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Nine studies were at low risk for other bias (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>; <a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). </p> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> was at unclear risk. </p> </section> </section> <section id="CD012623-sec-0061"> <h3 class="title" id="CD012623-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD012623-tbl-0001"><b>Summary of findings 1</b> Infliximab 5–10 mg/kg compared to placebo</a>; <a href="./full#CD012623-tbl-0002"><b>Summary of findings 2</b> Infliximab 5–10 mg/kg compared to placebo for exclusively fistulating population</a>; <a href="./full#CD012623-tbl-0003"><b>Summary of findings 3</b> Infliximab 5 mg/kg and purine analogues compared to purine analogues alone</a>; <a href="./full#CD012623-tbl-0004"><b>Summary of findings 4</b> Infliximab 5 mg/kg compared to purine analogues</a>; <a href="./full#CD012623-tbl-0005"><b>Summary of findings 5</b> Infliximab 5 mg/kg compared to infliximab 10 mg/kg</a>; <a href="./full#CD012623-tbl-0006"><b>Summary of findings 6</b> Infliximab 5 mg/kg compared to infliximab 10 mg/kg for exclusively fistulating population</a>; <a href="./full#CD012623-tbl-0007"><b>Summary of findings 7</b> Infliximab 5 mg/kg compared to infliximab 20 mg/kg</a>; <a href="./full#CD012623-tbl-0008"><b>Summary of findings 8</b> Infliximab 10 mg/kg compared to infliximab 20 mg/kg</a>; <a href="./full#CD012623-tbl-0009"><b>Summary of findings 9</b> Infliximab 5 mg/kg compared to CT‐P13 biosimilar 5 mg/kg</a> </p> <section id="CD012623-sec-0062"> <h4 class="title">Infliximab 5 mg/kg to 10 mg/kg versus placebo</h4> <p>Three studies compared infliximab to placebo on generalised CD populations (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>). <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> was on participants who did not respond to infliximab during the preliminary induction phase of RCTs assessing the effects of infliximab as maintenance therapy, and which randomised and followed up their non‐responder participants in parallel to the responders. </p> <section id="CD012623-sec-0063"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>Infliximab 5 mg/kg to 10 mg/kg may be more effective for clinical remission compared to placebo. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 30/55 participants receiving combined infliximab 5 mg/kg and 10 mg/kg doses achieved clinical remission at week four compared to 3/25 participants in the placebo group (RR 4.55, 95% CI 1.53 to 13.50; NNTB 3, 95% 2 to 9; low‐certainty evidence; <a href="./references#CD012623-fig-0003" title="">Analysis 1.1</a>; <a href="./full#CD012623-tbl-0001">summary of findings Table 1</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with imprecision and one level due to serious concerns risk of bias. </p> <p>The other studies did not report this outcome (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>). </p> </section> <section id="CD012623-sec-0064"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>Infliximab 5 mg/kg to 10 mg/kg may be more effective for clinical response compared to placebo. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported clinical response, defined as reduction of CDAI by 70 points or more at week four. This was achieved by 36/55 participants receiving 5 mg/kg and 10 mg/kg infliximab doses versus 4/24 participants in the placebo group (RR 4.09, 95% CI 1.63 to 10.25; NNTB 3, 95% CI 2 to 5; low‐certainty evidence; <a href="./references#CD012623-fig-0004" title="">Analysis 1.2</a>; <a href="./full#CD012623-tbl-0001">summary of findings Table 1</a>). </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> reported disease activity using the CDAI score at week four as a mean of 122.8 (SEM 26.1) for the 5 mg/kg group, 220.5 (SEM 63.4) for the 10 mg/kg group and 261.3 (SEM 33.3) for the placebo group. </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> did not report any data for this outcome. </p> </section> <section id="CD012623-sec-0065"> <h5 class="title">Primary outcome: withdrawal due to adverse events</h5> <p>No studies clearly reported withdrawal due to adverse events.</p> </section> <section id="CD012623-sec-0066"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>No studies clearly reported endoscopic remission.</p> </section> <section id="CD012623-sec-0067"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0068"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>We could not draw any conclusions on the effects of infliximab compared to placebo for endoscopic remission. </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> reported continuous endoscopic scores as a mean Crohn's Disease Endoscopic Index of Severity (CDEIS) scale score at week four. For the 5 mg/kg group this was 6.4 (SEM 5.1), for the 10 mg/kg group 4.3 (SEM 5.4), and for the placebo group 7.5 (SEM 5.4). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The remaining studies did not report this outcome.</p> </section> <section id="CD012623-sec-0069"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>No studies sufficiently reported serious adverse events.</p> </section> <section id="CD012623-sec-0070"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>No studies sufficiently reported total adverse events.</p> </section> </section> <section id="CD012623-sec-0071"> <h4 class="title">Infliximab 5 mg/kg to 10 mg/kg versus placebo for exclusively fistulating population</h4> <p>Two studies compared infliximab to placebo for exclusively fistulating CD populations (<a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>; <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a>). <a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> was on participants who did not respond to infliximab during the preliminary induction phase of RCTs assessing the effects of infliximab as maintenance therapy, and which randomised and followed up their non‐responder participants in parallel to the responders. </p> <section id="CD012623-sec-0072"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>We could not draw any conclusions on the effects of infliximab compared to placebo for clinical remission on exclusively fistulating participants. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported 29/63 participants receiving infliximab 5 mg/kg and 10 mg/kg versus 4/31 participants receiving placebo achieved clinical remission defined as absence of any draining fistulas at consecutive visits (RR 3.57, 95% CI 1.38 to 9.25; NNTB 4, 95% CI 2 to 13; very low‐certainty evidence; <a href="./references#CD012623-fig-0005" title="">Analysis 2.1</a>; <a href="./full#CD012623-tbl-0002">summary of findings Table 2</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and two levels due very serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> did not report this outcome. </p> </section> <section id="CD012623-sec-0073"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>We could not draw any conclusions on the effects of infliximab compared to placebo for clinical response on exclusively fistulating participants. </p> <p>Both studies reported clinical response defined as reduction of 50% in the number of draining fistulas at two or more consecutive visits. </p> <p>A total of 48/106 participants in the infliximab 5 mg/kg and 10 mg/kg groups versus 15/75 participants in the placebo group achieved clinical response (RR 1.94, 95% CI 1.10 to 3.41; I<sup>2</sup> = 14%; NNTB 6, 95% CI 3 to 32; very low‐certainty evidence; <a href="./full#CD012623-tbl-0002">summary of findings Table 2</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and two levels due to very serious concerns with imprecision. </p> </section> <section id="CD012623-sec-0074"> <h5 class="title">Primary outcome: withdrawal due to adverse events</h5> <p>We could not draw any conclusions on the effects of infliximab compared to placebo on withdrawals due to adverse events on exclusively fistulating participants. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported 2/63 participants withdrew due to adverse events in the infliximab 5 mg/kg and 10 mg/kg groups and 0/31 participants in the placebo group (RR 2.50, 95% CI 0.12 to 50.54; very low‐certainty evidence; <a href="./references#CD012623-fig-0007" title="">Analysis 2.3</a>; <a href="./full#CD012623-tbl-0002">summary of findings Table 2</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and two levels due to very serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> did not report this outcome. </p> </section> <section id="CD012623-sec-0075"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>No studies reported endoscopic remission.</p> </section> <section id="CD012623-sec-0076"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0077"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0078"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>We could not draw any conclusions on the effects of infliximab compared to placebo on serious adverse events on exclusively fistulating participants. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported 5/63 serious adverse events in the infliximab 5 mg/kg and 10 mg/kg groups and 0/31 events in the placebo group (RR 5.50, 95% CI 0.31 to 96.40; very low‐certainty evidence; <a href="./references#CD012623-fig-0008" title="">Analysis 2.4</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias, and two levels due to very serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> did not report this outcome. </p> </section> <section id="CD012623-sec-0079"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>We could not draw any conclusions on the effects of infliximab compared to placebo on total adverse events on exclusively fistulating participants. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported a total of 36/63 participants with adverse events in the infliximab 5 mg/kg and 10 mg/kg groups and 12/31 participants in the placebo group (RR 1.48, 95% CI 0.90 to 2.41; very low‐certainty evidence; <a href="./references#CD012623-fig-0009" title="">Analysis 2.5</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and two levels due to very serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> did not report this outcome. </p> </section> </section> <section id="CD012623-sec-0080"> <h4 class="title">Infliximab 5 mg/kg combined with purine analogues versus purine analogues</h4> <p>Four studies compared infliximab combined with azathioprine or 6‐mercaptopurine (purine analogues) to purine analogues alone. Two studies compared a combination group (infliximab and purine analogues) to infliximab alone and to purine analogues alone (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>). One study compared infliximab plus purine analogues to placebo plus purine analogues (<a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>). <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> also compared infliximab plus purine analogues to purine analogues alone. However, at week 14, they added infliximab to all participants in the purine analogues alone group (<a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>). Therefore, we used data prior to the addition of infliximab. </p> <section id="CD012623-sec-0081"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>All four studies were included in a meta‐analysis (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>). </p> <p>Infliximab used in combination with purine analogues is probably more effective at inducing remission in CD than purine analogues alone at 24 to 26 weeks (182/301 participants with infliximab plus purine analogues versus 95/302 participants with purine analogues alone; RR 1.92, 95% CI 1.59 to 2.32; I<sup>2</sup> = 0%; NNTB 4, 95% 3 to 5; 4 studies; moderate‐certainty evidence; <a href="./references#CD012623-fig-0010" title="">Analysis 3.1</a>; <a href="./full#CD012623-tbl-0003">summary of findings Table 3</a>). We downgraded the certainty of the evidence one level due to serious concerns with risk of bias. </p> <p>A sensitivity analysis using the fixed‐effect model produced similar results (RR 1.93, 95% CI 1.58 to 2.35; <a href="./references#CD012623-fig-0011" title="">Analysis 3.2</a>). </p> <p>A sensitivity analysis that considered only studies that included participants who were naive to biologicals produced similar results (RR 1.94, 95% CI 1.56 to 2.43; <a href="./references#CD012623-fig-0012" title="">Analysis 3.3</a>). </p> </section> <section id="CD012623-sec-0082"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>Two studies reported clinical response (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>). </p> <p>Infliximab used in combination with purine analogues is probably more effective at inducing response in CD than purine analogues alone at week 26 (107/177 participants with infliximab plus purine analogues versus 66/178 participants with purine analogues alone; RR 1.64, 95% CI 1.31 to 2.05; I<sup>2</sup> = 0%; NNTB 5, 95% CI 4 to 8; moderate‐certainty evidence; <a href="./references#CD012623-fig-0013" title="">Analysis 3.4</a>; <a href="./full#CD012623-tbl-0003">summary of findings Table 3</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome clearly.</p> </section> <section id="CD012623-sec-0083"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>Four studies contributed data for this outcome (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>). </p> <p>There may be little to no difference in the occurrence of withdrawals due to adverse events with infliximab and purine analogues compared to purine analogues alone (53/301 participants with infliximab plus purine analogues versus 62/302 participants with purine analogues alone; RR 0.87, 95% CI 0.63 to 1.21; low‐certainty evidence; <a href="./references#CD012623-fig-0014" title="">Analysis 3.5</a>; <a href="./full#CD012623-tbl-0003">summary of findings Table 3</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0084"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>Three studies reported endoscopic remission (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>). </p> <p>Infliximab used in combination with purine analogues may be more effective at inducing endoscopic remission than when using purine analogues alone (51/177 participants with infliximab plus purine analogues versus 21/178 participants with purine analogues alone; RR 2.27, 95% CI 1.31 to 3.94; I<sup>2</sup> = 15%; NNTB 6, 95% 4 to 15; low‐certainty evidence; <a href="./references#CD012623-fig-0015" title="">Analysis 3.6</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not report this outcome. </p> </section> <section id="CD012623-sec-0085"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0086"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0087"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>Three studies reported serious adverse events (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>). </p> <p>Infliximab used in combination with purine analogues may be no different to purine analogues alone for serious adverse effects (50/293 participants with infliximab plus purine analogues versus 65/294 participants with purine analogues alone; RR 0.79, 95% CI 0.55 to 1.11; I<sup>2</sup> = 7%; low‐certainty evidence; <a href="./references#CD012623-fig-0016" title="">Analysis 3.7</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not report this outcome. </p> </section> <section id="CD012623-sec-0088"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>Two studies reported total adverse events (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>; <a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a>). </p> <p>Infliximab used in combination with purine analogues may be no different to purine analogues alone for total adverse effects (82/226 participants with infliximab plus purine analogues versus 97/228 participants with purine analogues alone; RR 0.88, 95% CI 0.65 to 1.20; I<sup>2</sup> = 42%; low‐certainty evidence; <a href="./references#CD012623-fig-0017" title="">Analysis 3.8</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> <p>The other studies did not report this outcome.</p> </section> </section> <section id="CD012623-sec-0089"> <h4 class="title">Infliximab 5 mg/kg versus purine analogues</h4> <p>Two studies compared infliximab 5 mg/kg versus purine analogues (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a><i>;</i><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>). </p> <section id="CD012623-sec-0090"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>Both studies reported clinical remission.</p> <p>Infliximab may be more effective at inducing remission than when using purine analogues (85/177 participants with infliximab versus 57/178 participants with purine analogues; RR 1.50, 95% CI 1.15 to 1.95; I<sup>2</sup> = 0%; NNTB 7, 95% 4 to 19; low‐certainty evidence; <a href="./references#CD012623-fig-0018" title="">Analysis 4.1</a>; <a href="./full#CD012623-tbl-0004">summary of findings Table 4</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> </section> <section id="CD012623-sec-0091"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>Data from both studies were included in a meta‐analysis.</p> <p>Infliximab may be more effective at inducing clinical response than when using purine analogues at week 26 (94/177 participants with infliximab versus 66/178 participants with purine analogues; RR 1.44, 95% CI 1.13 to 1.82; I<sup>2</sup> = 0%; NNTB 7, 95% 4 to 18; low‐certainty evidence; <a href="./references#CD012623-fig-0019" title="">Analysis 4.2</a>; <a href="./full#CD012623-tbl-0004">summary of findings Table 4</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> </section> <section id="CD012623-sec-0092"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>Data from both studies were included in a meta‐analysis.</p> <p>Infliximab may be no different to purine analogues for withdrawals due to adverse events (30/177 participants with infliximab versus 43/178 participants with purine analogues; RR 0.70, 95% CI 0.46 to 1.06; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD012623-fig-0020" title="">Analysis 4.3</a>; <a href="./full#CD012623-tbl-0004">summary of findings Table 4</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> </section> <section id="CD012623-sec-0093"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>Data from both studies were included in a meta‐analysis.</p> <p>Infliximab may be no different to purine analogues for achievement of endoscopic remission (29/177 participants with infliximab versus 21/178 participants with purine analogues; RR 1.00, 95% CI 0.25 to 3.96; I<sup>2</sup> = 51%; low‐certainty evidence; <a href="./references#CD012623-fig-0021" title="">Analysis 4.4</a>). </p> <p>We downgraded the certainty of the evidence one level due to serious concerns with risk of bias and one level due to serious concerns with imprecision. </p> </section> <section id="CD012623-sec-0094"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0095"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0096"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>One study reported serious adverse events (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>). </p> <p>Infliximab may be no different to purine analogues for serious adverse events (39/169 participants with infliximab versus 43/170 participants with purine analogues; RR 0.91, 95% CI 0.63 to 1.33; low‐certainty evidence; <a href="./references#CD012623-fig-0022" title="">Analysis 4.5</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not report this outcome. </p> </section> <section id="CD012623-sec-0097"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>One study reported total adverse events (<a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a>). </p> <p>Infliximab may be no different to purine analogues for total adverse events (53/169 participants with infliximab versus 69/170 participants with purine analogues; RR 0.77, 95% CI 0.58 to 1.03; low‐certainty evidence; <a href="./references#CD012623-fig-0023" title="">Analysis 4.6</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision. </p> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> did not report this outcome. </p> </section> </section> <section id="CD012623-sec-0098"> <h4 class="title">Infliximab 5 mg/kg versus infliximab 10 mg/kg</h4> <p>Three studies compared infliximab 5 mg/kg to infliximab 10 mg/kg in a generalised CD population (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>). </p> <section id="CD012623-sec-0099"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 10 mg/kg for clinical remission. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 19/27 participants receiving infliximab 5 mg/kg achieved clinical remission compared to 11/28 participants receiving infliximab 10 mg/kg (RR 1.79, 95% CI 1.06 to 3.02; NNTB 4, 95% CI 3 to 23; <a href="./references#CD012623-fig-0024" title="">Analysis 5.1</a>; <a href="./full#CD012623-tbl-0005">summary of findings Table 5</a>). </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> did not provide a dichotomous definition for remission. They reported a mean CDAI score of 261.3 (SEM 33.3) for the infliximab 5 mg/kg group (eight participants) and 122.8 (SEM 26.1) for the 10 mg/kg group (eight participants). </p> <p>The evidence was very low certainty; we downgraded two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> did not report this outcome for their infliximab non‐responder participants. </p> </section> <section id="CD012623-sec-0100"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to 10 mg/kg for clinical response. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 22/27 participants receiving infliximab 5 mg/kg achieved clinical response compared to 14/28 participants receiving infliximab 10 mg/kg (RR 1.63, 95% CI 1.08 to 2.46; NNTB 4, 95% CI 3 to 16; very low‐certainty evidence; <a href="./references#CD012623-fig-0025" title="">Analysis 5.2</a>; <a href="./full#CD012623-tbl-0005">summary of findings Table 5</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0101"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>No studies clearly reported withdrawal due to adverse events.</p> </section> <section id="CD012623-sec-0102"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to 10 mg/kg for endoscopic remission. </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> did not provide a dichotomous definition for endoscopic remission. They reported a mean CDEIS score of 6.4 (SEM 5.1) for the infliximab 5 mg/kg group (eight participants) and 4.3 (SEM 5.4) for the 10 mg/kg group (eight participants). </p> <p>The evidence was very low certainty; we downgraded two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0103"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0104"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0105"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>No studies clearly reported serious adverse events.</p> </section> <section id="CD012623-sec-0106"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>No studies clearly reported total adverse events.</p> </section> </section> <section id="CD012623-sec-0107"> <h4 class="title">Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population</h4> <p>One study compared infliximab 5 mg/kg to infliximab 10 mg/kg in an exclusively fistulating CD population (<a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>). </p> <section id="CD012623-sec-0108"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 10 mg/kg for remission in an exclusively fistulating population. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported the remission rate was 17/31 in the infliximab 5 mg/kg group and 12/32 in the infliximab 10 mg/kg group (RR 1.46, 95% CI 0.84 to 2.53; very low‐certainty evidence; <a href="./references#CD012623-fig-0026" title="">Analysis 6.1</a>; <a href="./full#CD012623-tbl-0006">summary of findings Table 6</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> <section id="CD012623-sec-0109"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 10 mg/kg for response in an exclusively fistulating population. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported the response rate was 21/31 in the infliximab 5 mg/kg group and 18/32 in the infliximab 10 mg/kg group (RR 1.20, 95% CI 0.82 to 1.78; very low‐certainty evidence; <a href="./references#CD012623-fig-0027" title="">Analysis 6.2</a>; <a href="./full#CD012623-tbl-0006">summary of findings Table 6</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> <section id="CD012623-sec-0110"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 10 mg/kg on withdrawals due to adverse events in an exclusively fistulating population. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported withdrawals due to adverse events as 1/31 in the 5 mg/kg group and 1/32 in the 10 mg/kg group (RR 1.03, 95% CI 0.07 to 15.79; very low‐certainty evidence; <a href="./references#CD012623-fig-0028" title="">Analysis 6.3</a>; <a href="./full#CD012623-tbl-0006">summary of findings Table 6</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> <section id="CD012623-sec-0111"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>No studies reported endoscopic remission.</p> </section> <section id="CD012623-sec-0112"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0113"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0114"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 10 mg/kg on serious adverse events in an exclusively fistulating population. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported serious adverse events as 1/31 in the infliximab 5 mg/kg group and 4/32 in the infliximab 10 mg/kg group (RR 0.26, 95% CI 0.03 to 2.18; very low‐certainty evidence; <a href="./references#CD012623-fig-0029" title="">Analysis 6.4</a>; <a href="./full#CD012623-tbl-0006">summary of findings Table 6</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> <section id="CD012623-sec-0115"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 10 mg/kg on total adverse events in an exclusively fistulating population. </p> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> reported total adverse events as 10/31 in the infliximab 5 mg/kg group and 26/32 in the infliximab 10 mg/kg group (RR 0.40, 95% CI 0.23 to 0.68; very low‐certainty evidence; <a href="./references#CD012623-fig-0030" title="">Analysis 6.5</a>; <a href="./full#CD012623-tbl-0006">summary of findings Table 6</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> </section> <section id="CD012623-sec-0116"> <h4 class="title">Infliximab 5 mg/kg versus infliximab 20 mg/kg</h4> <p>Two studies compared infliximab 5 mg/kg to infliximab 20 mg/kg (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>) </p> <section id="CD012623-sec-0117"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 20 mg/kg for clinical remission. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 19/27 participants receiving infliximab 5 mg/kg achieved clinical remission compared to 11/28 participants receiving infliximab 20 mg/kg (RR 1.79, 95% CI 1.06 to 3.02; NNTB 4, 95% CI 3 to 23; <a href="./references#CD012623-fig-0031" title="">Analysis 7.1</a>; <a href="./full#CD012623-tbl-0007">summary of findings Table 7</a>). </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> did not provide a dichotomous definition for remission. They reported a mean CDAI score of 261.3 (SEM 33.3) for the infliximab 5 mg/kg group (eight participants) and 161.9 (SEM 34.5) for the 20 mg/kg group (eight participants). </p> <p>The evidence was very low certainty; we downgraded two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> <section id="CD012623-sec-0118"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 20 mg/kg for clinical response. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 22/27 participants receiving infliximab 5 mg/kg achieved clinical response compared to 18/28 participants receiving infliximab 20 mg/kg (RR 1.27, 95% CI 0.91 to 1.76; very low‐certainty evidence; <a href="./references#CD012623-fig-0032" title="">Analysis 7.2</a>; <a href="./full#CD012623-tbl-0007">summary of findings Table 7</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0119"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>No studies clearly reported withdrawals due to adverse events.</p> </section> <section id="CD012623-sec-0120"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>We could not draw any conclusions on the effects of infliximab 5 mg/kg compared to infliximab 20 mg/kg for endoscopic remission. </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> did not provide a dichotomous definition for endoscopic remission. They reported a mean CDEIS score of 6.4 (SEM 5.1) for the infliximab 5 mg/kg group (eight participants) and 5.2 (SEM 2.8) for the infliximab 20 mg/kg group (eight participants). </p> <p>The evidence was very low certainty; we downgraded two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0121"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0122"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0123"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>No studies clearly reported serious adverse events.</p> </section> <section id="CD012623-sec-0124"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>No studies clearly reported total adverse events.</p> </section> </section> <section id="CD012623-sec-0125"> <h4 class="title">Infliximab 10 mg/kg versus infliximab 20 mg/kg</h4> <p>Two studies compared infliximab 10 mg/kg to infliximab 20 mg/kg (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a>). </p> <section id="CD012623-sec-0126"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>We could not draw any conclusions on the effects of infliximab 10 mg/kg compared to infliximab 20 mg/kg for clinical remission. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 11/28 participants receiving infliximab 10 mg/kg achieved clinical remission compared to 11/28 participants receiving infliximab 20 mg/kg (RR 1.00, 95% CI 0.52 to 1.92; <a href="./references#CD012623-fig-0033" title="">Analysis 8.1</a>; <a href="./full#CD012623-tbl-0008">summary of findings Table 8</a>). </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> did not provide a dichotomous definition for remission. They reported a mean CDAI score of 220.5 (SEM 63.4) for the infliximab 10 mg/kg group (eight participants) and 161.9 (SEM 34.5) for the infliximab 20 mg/kg group (eight participants). </p> <p>The evidence was very low certainty; we downgraded two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> </section> <section id="CD012623-sec-0127"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>We could not draw any conclusions on the effects of infliximab 10 mg/kg compared to infliximab 20 mg/kg for clinical response. </p> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> reported 14/28 participants receiving infliximab 5 mg/kg achieved clinical response compared to 18/28 receiving infliximab 20 mg/kg (RR 0.78, 95% CI 0.49 to 1.23; very low‐certainty evidence; <a href="./references#CD012623-fig-0034" title="">Analysis 8.2</a>; <a href="./full#CD012623-tbl-0008">summary of findings Table 8</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0128"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>No studies clearly reported withdrawals due to adverse events.</p> </section> <section id="CD012623-sec-0129"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>We could not draw any conclusions on the effects of infliximab 10 mg/kg compared to infliximab 20 mg/kg for endoscopic remission. </p> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> did not provide a dichotomous definition for endoscopic remission. They reported a mean CDEIS score of 4.3 (SEM 5.4) for the infliximab 10 mg/kg group (eight participants) and 5.2 (SEM 2.8) for the infliximab 20 mg/kg group (eight participants). </p> <p>The evidence was of very low certainty; we downgraded two levels due to very serious concerns with imprecision and one level due to serious concerns with risk of bias. </p> <p>The other studies did not report this outcome.</p> </section> <section id="CD012623-sec-0130"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0131"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0132"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>No studies clearly reported serious adverse events.</p> </section> <section id="CD012623-sec-0133"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>No studies clearly reported total adverse events.</p> </section> </section> <section id="CD012623-sec-0134"> <h4 class="title">Infliximab 5 mg/kg versus CT‐P13 biosimilar at 5 mg/kg</h4> <p>Only one study compared infliximab to a biosimilar (<a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>). </p> <section id="CD012623-sec-0135"> <h5 class="title">Primary outcome: achievement of clinical remission</h5> <p>Infliximab may be equal to the biosimilar for the achievement of clinical remission (47/109 participants with infliximab 5 mg/kg versus 49/111 participants with biosimilar; RR 0.98, 95% CI 0.72 to 1.32; low‐certainty evidence; <a href="./references#CD012623-fig-0035" title="">Analysis 9.1</a>; <a href="./full#CD012623-tbl-0009">summary of findings Table 9</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious imprecision.</p> </section> <section id="CD012623-sec-0136"> <h5 class="title">Primary outcome: achievement of clinical response</h5> <p>Infliximab may be equal to the biosimilar for the achievement of clinical response (67/109 participants with infliximab 5 mg/kg versus 70/111 participants with biosimilar; RR 0.97, 95% CI 0.79 to 1.20; low‐certainty evidence; <a href="./references#CD012623-fig-0036" title="">Analysis 9.2</a>; <a href="./full#CD012623-tbl-0009">summary of findings Table 9</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious imprecision.</p> </section> <section id="CD012623-sec-0137"> <h5 class="title">Primary outcome: withdrawals due to adverse events</h5> <p>Infliximab may be similar to the biosimilar for withdrawals due to adverse events (21/109 participants with infliximab 5 mg/kg versus 17/111 participants with biosimilar; RR 1.26, 95% CI 0.70 to 2.25; low‐certainty evidence; <a href="./references#CD012623-fig-0037" title="">Analysis 9.3</a>; <a href="./full#CD012623-tbl-0009">summary of findings Table 9</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious imprecision.</p> </section> <section id="CD012623-sec-0138"> <h5 class="title">Secondary outcome: endoscopic remission</h5> <p>No studies reported endoscopic remission.</p> </section> <section id="CD012623-sec-0139"> <h5 class="title">Secondary outcome: histological remission</h5> <p>No studies reported histological remission.</p> </section> <section id="CD012623-sec-0140"> <h5 class="title">Secondary outcome: endoscopic response</h5> <p>No studies reported endoscopic response.</p> </section> <section id="CD012623-sec-0141"> <h5 class="title">Secondary outcome: serious adverse events</h5> <p>Infliximab may be similar to the biosimilar for serious adverse events (9/109 participants with infliximab 5 mg/kg versus 6/111 participants with biosimilar; RR 1.53, 95% CI 0.56 to 4.15; low‐certainty evidence; <a href="./references#CD012623-fig-0038" title="">Analysis 9.4</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious imprecision.</p> </section> <section id="CD012623-sec-0142"> <h5 class="title">Secondary outcome: total adverse events</h5> <p>Infliximab may be similar to the biosimilar for total adverse events (70/109 participants with infliximab 5 mg/kg versus 93/111 participants with biosimilar; RR 1.13, 95% CI 0.91 to 1.40; low‐certainty evidence; <a href="./references#CD012623-fig-0039" title="">Analysis 9.5</a>). </p> <p>We downgraded the certainty of the evidence two levels due to very serious imprecision.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012623-sec-0143" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012623-sec-0143"></div> <section id="CD012623-sec-0144"> <h3 class="title" id="CD012623-sec-0144">Summary of main results</h3> <p>This review included 10 RCTs with 1101 randomised participants.</p> <p>Infliximab may be more effective for inducing clinical remission and response than placebo. </p> <p>Infliximab used in combination with purine analogues is probably more effective for inducing clinical remission than purine analogues alone (NNTB 4) and for inducing clinical response (NNTB 5). There may be little or no difference in the occurrence of withdrawals due to adverse events, the number of serious adverse events and the total number of adverse events. Infliximab and purine analogues combined may be more effective for endoscopic remission than purine analogues alone (NNTB 6). </p> <p>Infliximab alone may be more effective for inducing clinical remission (NNTB 7) and response (NNTB 7) than purine analogues alone. There may be little or no difference in withdrawals due to adverse events, the number of serious adverse events and the total number of adverse events. There may be little or no difference between infliximab alone and purine analogues alone for endoscopic remission. </p> <p>There may be little or no difference between infliximab and a CT‐P13 biosimilar for inducing clinical remission, clinical response and withdrawals due to adverse events. </p> <p>We could not draw any conclusions when comparing infliximab 5 mg/kg to 10 mg/kg, 5 mg/kg to 20 mg/kg and 10 mg/kg to 20 mg/kg, for clinical remission or response, in a general CD population, because the certainty of the evidence was very low. </p> <p>We could not draw any conclusions for all outcomes in the exclusively fistulating studies, including for the comparison of infliximab 5 mg/kg to 10 mg/kg compared to placebo. </p> <p>We could not draw any conclusions for other outcomes because the available evidence was of very low certainty, or had not been reported. </p> </section> <section id="CD012623-sec-0145"> <h3 class="title" id="CD012623-sec-0145">Overall completeness and applicability of evidence</h3> <p>The evidence is incomplete for several reasons. Given that the studies spanned 23 years between the first included studies (<a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a>; <a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a>) and the latest study (<a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a>), there have been changes in practice. These are associated with changes in definition of the disease and response that have contributed to heterogeneity of the patient populations and outcome measures employed that all limit the applicability of the evidence synthesised. </p> <p>Most studies included in this review used the CDAI to recruit participants to studies and assessed clinical remission and response at different endpoints, which is considered the standard tool in CD research. However, other measures of disease state and in turn endpoints for studies, such as endoscopic and histological measures, were limited in reporting. </p> <p>Moreover, in some contexts within CD, homogeneity of participants at entry is perhaps implicit, such as after surgery (<a href="./references#CD012623-bbs2-0069" title="Gjuladin-HellonT , Iheozor-Ejiofor, GordonM , AkobengAK . Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD010233. [DOI: 10.1002/14651858.CD010233.pub3]">Gjuladin‐Hellon 2019a</a>; <a href="./references#CD012623-bbs2-0070" title="Gjuladin-HellonT , GordonM , Iheozor-EjioforZ , AkobengAK . Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD008414. [DOI: 10.1002/14651858.CD008414.pub3]">Gjuladin‐Hellon 2019b</a>; <a href="./references#CD012623-bbs2-0077" title="Iheozor-EjioforZ , GordonM , CleggA , FreemanSC , Gjuladin-HellonT , MacDonaldJK , et al. Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013210. [DOI: 10.1002/14651858.CD013210.pub2]">Iheozor‐Ejiofor 2019</a>). The studies included in this review involved people with different pre‐recruitment experience of therapy, as well as length and severity of disease. It has been demonstrated that a top‐down approach involving early biological and immunosuppressant use can lead to better results than using these in non‐responders (<a href="./references#CD012623-bbs2-0061" title="BaertF , MoortgatL , vanAsscheG , CaenepeelP , VergauweP , De VosM , et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology2010;138(2):463-8.">Baert 2010</a>; <a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a>). The disease state of participants and prior experience are key clinical factors that cannot be commented on due to the heterogeneity of the populations included in the primary studies. </p> <p>This review found that trials mostly compared infliximab to a placebo or active comparator. However, with the increasing use of other biological drugs, the evidence in this area of practice is lacking. </p> <p>The reporting of adverse events is another area of concern. It is common to experience difficulties in reporting related to heterogeneity of thresholds in defining serious or severe events, and as such, withdrawals are often the most available measure. For common effects, RCT data can be sufficient to consider safety (<a href="./references#CD012623-bbs2-0071" title="GordonM , Grafton-ClarkeC , AkobengA , MacdonaldJ , ChandeN , HanauerS , et al. Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review. Frontline Gastroenterology2021;12:423-36.">Gordon 2021a</a>), but this is not the case for rarer and possibly more devastating outcomes where long‐term safety data are not addressed by this synthesis. </p> <p>Finally, sample size of trials has resulted in issues with precision in most GRADE analyses. This is a pervasive issue within the field (<a href="./references#CD012623-bbs2-0078" title="Iheozor-EjioforZ , LakuninaS , GordonM , AkintelureD , SinopoulouV , AkobengA . Sample-size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: a systematic review. UEG Journal2021;9:47-53.">Iheozor‐Ejiofor 2021</a>). </p> <p>This review did not include comparisons of routes of administration for infliximab, such as intravenous compared to subcutaneous. Future updates of this review will consider investigating this. </p> </section> <section id="CD012623-sec-0146"> <h3 class="title" id="CD012623-sec-0146">Quality of the evidence</h3> <p>There were issues with unclear bias due to selective reporting. The older studies rarely reported protocols or registered trials and impacted the certainty of most GRADE judgements. </p> <p>The certainty of outcomes on GRADE analysis range from moderate to very low, with the impact of both risk of bias and imprecision as key factors impacting the certainty of the evidence. Reporting of adverse events was also very sparse and so this was reflected in the GRADE analysis. </p> </section> <section id="CD012623-sec-0147"> <h3 class="title" id="CD012623-sec-0147">Potential biases in the review process</h3> <p>Gaps in information to judge risk of bias was pervasive. We chose to contact the study authors for clarification or additional information; however, not all authors responded. We aim to include the data that may become available in future updates, but this could represent a source of bias in the review. </p> <p>One study published the abstract in English while the full‐text article was in Chinese. We translated the study electronically as we were unable to find any contact information for the author group, so this may lead to a reporting bias (<a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a>). </p> <p>We are aware of the possibility of industry funding impacting the validity of the results. Funding from manufacturing companies or any conflicts of interests from both primary studies and the review team have been reported. </p> <p>To our knowledge, this is the first Cochrane Review to specifically study the induction phase of infliximab and explicitly consider concurrent therapy with purine analogues. In some studies, this was the explicit goal of the study, but in others, the presence of such therapy (or indeed its absence) was only mentioned in a cursory manner. We believe this reflects a highly important clinical factor and source of heterogeneity and have, therefore, categorised studies as accurately as possible. However, this categorisation could be considered a source of bias. </p> </section> <section id="CD012623-sec-0148"> <h3 class="title" id="CD012623-sec-0148">Agreements and disagreements with other studies or reviews</h3> <p>The previous Cochrane Review that assessed the overall efficacy and safety of TNF‐α antagonists had similar results showing the effectiveness of anti‐TNF agents in inducing remission in CD (<a href="./references#CD012623-bbs2-0059" title="AkobengAK , ZachosM . Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD003574. [DOI: 10.1002/14651858.CD003574.pub2]">Akobeng 2003</a>). </p> <p>The results broadly support current international guidelines in the UK (<a href="./references#CD012623-bbs2-0081" title="LambCA , KennedyNA , RaineT , HendyPA , SmithPJ , LimdiJK , et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut2019;68(3):s1-106.">Lamb 2019</a>), Europe (<a href="./references#CD012623-bbs2-0095" title="TorresJ , BonovasS , DohertyG , KucharzikT , GisbertJP , RaineT , et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. Journal of Crohn's and colitis2020;14:4-22.">Torres 2020</a>), and North America (<a href="./references#CD012623-bbs2-0068" title="FeuersteinJD , HoEY , ShmidtE , SinghH , Falck-YtterY , SultanS , et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology2021;160:2496-508.">Feuerstein 2021</a>). However, the GRADE certainty ratings in these guidelines are higher than the judgements in this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012623-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012623-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012623-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Infliximab 5–10 mg/kg versus placebo, Outcome 1: Clinical remission defined as CDAI &lt; 150 by week 4" data-id="CD012623-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Infliximab 5–10 mg/kg versus placebo, Outcome 1: Clinical remission defined as CDAI &lt; 150 by week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Infliximab 5–10 mg/kg versus placebo, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 70 at week 4" data-id="CD012623-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Infliximab 5–10 mg/kg versus placebo, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 70 at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 1: Clinical remission defined as absence of any draining fistulas at consecutive visits" data-id="CD012623-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 1: Clinical remission defined as absence of any draining fistulas at consecutive visits </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 2: Clinical response defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits" data-id="CD012623-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 2: Clinical response defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 3: Withdrawals due to adverse events" data-id="CD012623-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 3: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 4: Serious adverse events" data-id="CD012623-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 5: Total adverse events" data-id="CD012623-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population, Outcome 5: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 1: Clinical remission as defined by the studies at weeks 24–26" data-id="CD012623-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 1: Clinical remission as defined by the studies at weeks 24–26 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 2: Clinical remission as defined by the studies (sensitivity analysis for fixed effects)" data-id="CD012623-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 2: Clinical remission as defined by the studies (sensitivity analysis for fixed effects) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 3: Clinical remission as defined by the studies (sensitivity analysis for biologically naive patients)" data-id="CD012623-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 3: Clinical remission as defined by the studies (sensitivity analysis for biologically naive patients) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 4: Clinical response as defined by the studies at week 26" data-id="CD012623-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 4: Clinical response as defined by the studies at week 26 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 5: Withdrawals due to adverse events" data-id="CD012623-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 5: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 6: Endoscopic remission as defined by the studies" data-id="CD012623-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 6: Endoscopic remission as defined by the studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 7: Serious adverse events" data-id="CD012623-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 7: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 8: Total adverse events" data-id="CD012623-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Infliximab 5 mg/kg and purine analogues versus purine analogues, Outcome 8: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 1: Clinical remission at week 26" data-id="CD012623-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 1: Clinical remission at week 26 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 2: Clinical response at week 26" data-id="CD012623-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 2: Clinical response at week 26 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 3: Withdrawals due to adverse events" data-id="CD012623-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 3: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 4: Endoscopic remission" data-id="CD012623-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 4: Endoscopic remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 5: Serious adverse events" data-id="CD012623-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 5: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 6: Total adverse events" data-id="CD012623-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Infliximab 5 mg/kg versus purine analogues, Outcome 6: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Infliximab 5 mg/kg versus infliximab 10 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 4" data-id="CD012623-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Infliximab 5 mg/kg versus infliximab 10 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Infliximab 5 mg/kg versus infliximab 10 mg/kg, Outcome 2: Clinical response defined as reduction in CDAI by 70 points at week 4" data-id="CD012623-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Infliximab 5 mg/kg versus infliximab 10 mg/kg, Outcome 2: Clinical response defined as reduction in CDAI by 70 points at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 1: Clinical remission defined by closure of all fistulae" data-id="CD012623-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 1: Clinical remission defined by closure of all fistulae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 2: Clinical response defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits" data-id="CD012623-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 2: Clinical response defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 3: Withdrawals due to adverse events" data-id="CD012623-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 3: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 4: Serious adverse events" data-id="CD012623-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 5: Total adverse events" data-id="CD012623-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population, Outcome 5: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Infliximab 5 mg/kg versus infliximab 20 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 4" data-id="CD012623-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Infliximab 5 mg/kg versus infliximab 20 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Infliximab 5 mg/kg versus infliximab 20 mg/kg, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 70 at week 4" data-id="CD012623-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Infliximab 5 mg/kg versus infliximab 20 mg/kg, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 70 at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Infliximab 10 mg/kg versus infliximab 20 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 4" data-id="CD012623-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Infliximab 10 mg/kg versus infliximab 20 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Infliximab 10 mg/kg versus infliximab 20 mg/kg, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 70 at week 4" data-id="CD012623-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Infliximab 10 mg/kg versus infliximab 20 mg/kg, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 70 at week 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 6" data-id="CD012623-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 1: Clinical remission defined as CDAI &lt; 150 at week 6 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 100 at week 6" data-id="CD012623-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 2: Clinical response defined as reduction of CDAI score by ≥ 100 at week 6 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 3: Withdrawals due to adverse events" data-id="CD012623-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 3: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 4: Serious adverse events" data-id="CD012623-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012623-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/urn:x-wiley:14651858:media:CD012623:CD012623-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 5: Total adverse events" data-id="CD012623-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_t/tCD012623-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Infliximab 5 mg/kg versus biosimilar 5 mg/kg, Outcome 5: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/media/CDSR/CD012623/image_n/nCD012623-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Infliximab 5–10 mg/kg compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Amsterdam, Belgium, the Netherlands, UK, USA)<br/><b>Intervention:</b> infliximab <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> <p>defined as CDAI &lt; 150 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>546 per 1000<br/>(184 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.55</b><br/>(1.53 to 13.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> </p> <p>defined as improvement in the scores on the CDAI score ≥ 70 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>654 per 1000 (260 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.09</b> (1.63 to 10.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and one level due to serious concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Infliximab 5–10 mg/kg compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Infliximab 5–10 mg/kg compared to placebo for exclusively fistulating population</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to placebo for exclusively fistulating population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> not reported (multiple countries)<br/><b>Intervention:</b> infliximab (combined 5 and 10 mg/kg dosages)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460 per 1000</p> <p>(178 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.57</b> (1.38 to 9.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>388 per 1000</p> <p>(220 to 682)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.94</b> (1.10 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.5 per 1000</p> <p>(0 to 152)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.50</b> (0.12 to 50.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to very serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Infliximab 5–10 mg/kg compared to placebo for exclusively fistulating population</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Infliximab 5 mg/kg and purine analogues compared to purine analogues alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab and purine analogues compared to purine analogues alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Austria, Belgium, Canada, China, Denmark, France, Germany, Greece, Israel, Mexico, the Netherlands, Norway, Spain, Sweden, UK, USA)<br/><b>Intervention:</b> infliximab and purine analogues<br/><b>Comparison:</b> purine analogues </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with purine analogues</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with infliximab and purine analogues</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> as defined by the studies at weeks 24–26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>604 per 1000 (499 to 728)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.92</b> (1.59 to 2.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> as defined by the studies at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000 (486 to 760)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.64</b> (1.31 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000 (129 to 248)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> (0.63 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>603</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting.<br/><sup>b</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision from low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Infliximab 5 mg/kg and purine analogues compared to purine analogues alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Infliximab 5 mg/kg compared to purine analogues</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to purine analogues</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease<br/><b>Setting:</b> hospitals and tertiary centres (Belgium, Canada, China, Denmark, Sweden, USA)<br/><b>Intervention:</b> infliximab <br/><b>Comparison:</b> purine analogues </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with purine analogues</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000 (368 to 624)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (1.15 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> at week 26 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000 (432 to 695)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b> (1.13 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>241 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000 (111 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> (0.46 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision from low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Infliximab 5 mg/kg compared to purine analogues</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 10 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab 5 mg/kg compared to infliximab 10 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Belgium, England, Germany, the Netherlands, USA)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> infliximab 10 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 10 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 5 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as CDAI &lt; 150 at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>703 per 1000 (417 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> (1.06 to 3.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined as reduction in CDAI by 70 points at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>815 per 1000</p> <p>(540 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.63</b> (1.08 to 2.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and two levels due to concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 10 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 10 mg/kg for exclusively fistulating population</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab 5 mg/kg compared to infliximab 10 mg/kg for exclusively fistulating population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> not reported (multiple countries)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> infliximab 10 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 10 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 5 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median length of time of 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>548 per 1000</p> <p>(315 to 949)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> (0.84 to 2.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>563 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>675 per 1000 (462 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> (0.82 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> <p>(2 to 505)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> (0.07 to 15.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias for randomisation, blinding and selective reporting, and one level due to serious concerns with imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 10 mg/kg for exclusively fistulating population</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 20 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Infliximab 5 mg/kg compared to infliximab 20 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Belgium, England, Germany, the Netherlands, USA)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> infliximab 20 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with infliximab 20 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with infliximab 5 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>703 per 1000</p> <p>(417 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> </p> <p>(1.06 to 3.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> as defined by the studies week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000 (540 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b> (0.91 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and two levels due to very serious concerns with imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Infliximab 5 mg/kg compared to infliximab 20 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Infliximab 10 mg/kg compared to infliximab 20 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab 10 mg/kg compared to infliximab 20 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> hospitals and tertiary centres (Belgium, England, Germany, the Netherlands, USA)<br/><b>Intervention:</b> infliximab 10 mg/kg<br/><b>Comparison:</b> infliximab 20 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 20 mg/kg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab 10 mg/kg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as CDAI &lt; 150 at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> <p>(204 to 755)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.52 to 1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined by reduction of CDAI score by ≥ 70 at week 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>501 per 1000</p> <p>(315 to 791)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> </p> <p>(0.49 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious concerns with risk of bias (selective reporting and unclear randomisation), and two levels due to very serious concerns with imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Infliximab 10 mg/kg compared to infliximab 20 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012623-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Infliximab 5 mg/kg compared to CT‐P13 biosimilar 5 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Infliximab compared to biosimilar</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> active Crohn's disease <br/><b>Setting:</b> 58 centres in 16 countries (Belgium, Brazil, Denmark, France, Germany, Hungary, Italy, Israel, Mexico, the Netherlands, Poland, Republic of Korea, Romania, Russia, Ukraine, USA)<br/><b>Intervention:</b> infliximab 5 mg/kg<br/><b>Comparison:</b> CT‐P13 biosimilar 5 mg/kg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with infliximab</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with CT‐P13 biosimilar</p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> defined as CDAI &lt; 150 at week 6 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> <p>(317 to 582)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> (0.72 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> defined by reduction of CDAI score by ≥ 100 at week 6 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>631 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>612 per 1000</p> <p>(498 to 757)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> (0.79 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000</p> <p>(107 to 344)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> (0.70 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDAI:</b> Crohn's Disease Activity Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to very serious concerns with imprecision due to very low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Infliximab 5 mg/kg compared to CT‐P13 biosimilar 5 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012623-tbl-0010"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies' characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Numbers randomised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Purine analogues use</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Biological naive or not</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> combination therapy </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 508</p> <p><b>IG1:</b> 169 </p> <p><b>IG2:</b> 169 </p> <p><b>CG:</b> 170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg </p> <p><b>IG2:</b> IFX 10 mg </p> <p><b>IG3:</b> IFX 20 mg </p> <p><b>CG:</b> placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 30</p> <p><b>IG1:</b> 7 </p> <p><b>IG2:</b> 7 </p> <p><b>IG3:</b> 8 </p> <p><b>CG:</b> 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concomitant azathioprine</p> <p><b>IG1:</b> 3/7 </p> <p><b>IG2:</b> 1/7 </p> <p><b>IG3:</b> 5/8 </p> <p><b>CG:</b> 3/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg + AZA 2–2.5 mg/kg </p> <p><b>CG:</b> corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 133</p> <p><b>IG1:</b> 67 </p> <p><b>CG:</b> 66 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> AZA 2.5 mg/kg + IFX 5 mg/kg </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 24</p> <p><b>IG1:</b> 8 </p> <p><b>IG2:</b> 8 </p> <p><b>CG:</b> 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX infusion, regimen 1 </p> <p><b>IG2:</b> IFX infusion, regimen 2 </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 238</p> <p><b>IG1:</b> 79 </p> <p><b>IG2:</b> 81 </p> <p><b>CG:</b> 78 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only reported for the whole cohort (238 participants)</p> <p>5‐ASA: 288</p> <p>AZA/6‐MP: 63</p> <p>Methotrexate: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 115</p> <p><b>IG:</b> 57 </p> <p><b>CG:</b> 58 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Part of the intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> IFX 10 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 94</p> <p><b>IG1:</b> 31 </p> <p><b>IG2:</b> 32 </p> <p><b>CG:</b> 31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine or azathioprine:</p> <p><b>IG1:</b> 12/31 </p> <p><b>IG2:</b> 17/32 </p> <p><b>CG:</b> 9/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 87</p> <p><b>IG:</b> 43 </p> <p><b>CG:</b> 44 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine or azathioprine:</p> <p>Overall: 53/87 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> cA2 at 5 mg/kg </p> <p><b>IG2:</b> cA2 at 10 mg/kg </p> <p><b>IG3:</b> cA2 at 20 mg/kg </p> <p><b>CG:</b> 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total randomised: 108</p> <p><b>IG1:</b> 27 </p> <p><b>IG2:</b> 28 </p> <p><b>IG3:</b> 28 </p> <p><b>CG:</b> 25 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 4 </p> <p>Azathioprine:</p> <p><b>IG1:</b> 5 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 8 </p> <p><b>CG:</b> 7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> CT‐P13 biosimilar 5 mg/kg </p> <p><b>CG:</b> IFX 5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number randomised: 220</p> <p><b>IG:</b> 111 </p> <p><b>CG:</b> 109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mercaptopurine or azathioprine:</p> <p><b>IG:</b> 84/111 </p> <p><b>CG:</b> 80/109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>5‐ASA: 5‐aminosalicylic acid; 6‐MP: 6‐mercaptopurine; AZA: azathioprine; cA2: early name for infliximab; IFX: infliximab; CG: control group; IG: intervention group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies' characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012623-tbl-0011"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Included studies' intervention details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention medications</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Previous experience of biological therapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Medications up to starting study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Medications that had to be discontinued prior to starting study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mandatory medications per study protocol</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant medications during study</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX only. IV infusion of IFX 5 mg/kg at weeks 0, 2, 6, 14 and 22, plus daily oral placebo capsules through 30 weeks </p> <p><b>IG2:</b> combination therapy. IV infusion of IFX 5 mg/kg at weeks 0, 2, 6, 14 and 22 plus daily oral AZA capsules 2.5 mg/kg through 30 weeks </p> <p><b>CG:</b> AZA only. Daily oral capsules 2.5 mg/kg through 30 weeks plus placebo IV infusion at weeks 0, 2, 6, 14 and 22 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> <p>All participants naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1</b> </p> <p>No steroids: 117</p> <p>Steroids &lt; 20 mg: 19</p> <p>Steroids &gt; 20 mg: 33</p> <p>Budesonide: 28</p> <p>5‐ASA: 87</p> <p><b>IG2</b> </p> <p>No steroids: 122</p> <p>Steroids &lt; 20 mg: 14</p> <p>Steroids &gt; 20 mg: 33</p> <p>Budesonide: 19</p> <p>5‐ASA: 85</p> <p><b>CG</b> </p> <p>No steroids: 130</p> <p>Steroids &lt; 20 mg: 14</p> <p>Steroids &gt; 20 mg: 26</p> <p>Budesonide: 25</p> <p>5‐ASA: 104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic steroids</p> <p><b>IG1:</b> 60 </p> <p><b>IG2:</b> 58 </p> <p><b>CG:</b> 60 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> single IV dose IFX 5 mg/kg </p> <p><b>IG2:</b> single IV dose IFX 10 mg/kg </p> <p><b>IG3:</b> single IV dose IFX 20 mg/kg </p> <p><b>CG:</b> single IV dose of placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> <p><i>(exclusion criteria)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 3 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 5 </p> <p>AZA:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 3 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> single IV dose IFX 5 mg/kg at weeks 0, 2, 6 with AZA 2–2.5 mg/kg per day. </p> <p>If not tolerating AZA, 6‐MP given initial dose of 25 mg each week for 12 weeks with the dose reduced to 15 mg/week thereafter </p> <p><b>IG2:</b> corticosteroids then AZA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (exclusion criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (exclusion criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> AZA 50/65 (77%) </p> <p>MTX 16/65(25%)</p> <p><b>IG2:</b> AZA 38/64 (60%) </p> <p>MTX 8/64 (13%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IV IFX 5 mg/kg at weeks 0, 2 and 6 to induce remission followed by IFX 5 mg/kg every 8 weeks to maintain remission </p> <p><b>IG2:</b> AZA PO 2.5 mg/kg qd, and IV IFX 5 mg/kg at weeks 0, 2 and 6 to induce remission, followed by IFX 5 mg/kg every 8 weeks to maintain remission </p> <p><b>CG:</b> AZA PO 2.5 mg/kg qd </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At week 0, all eligible participants received IFX 5 mg/kg IV</p> <p><b>IG1:</b> IFX 5 mg/kg infusions at week 2, 6 and every 8 weeks thereafter until week 46 </p> <p><b>IG2:</b> IFX 10 mg/kg infusions at weeks 2, 6 and every 8 weeks thereafter until week 46 </p> <p><b>CG:</b> placebo infusions at weeks 2, 6 and every 8 weeks thereafter until week 46 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were excluded from the study if they had received previous treatment with IFX or any other agent targeted at TNF </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA: 129</p> <p>6‐MP and AZA: 63</p> <p>MTX: 13</p> <p>Corticosteroids of which:</p> <p>any – 118</p> <p>&gt; 20 mg/day: 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants not receiving medical therapy had to have discontinued treatment for ≥ 4 weeks before screening </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same as medications up to the start of study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants were treated with AZA/6‐MP 2–3 mg/kg</p> <p> <ul id="CD012623-list-0011"> <li> <p>Failure stratum (56 enroled):</p> <ul id="CD012623-list-0012"> <li> <p><b>IG:</b> 26 IFX 0, 2 and 6 weeks at 5 mg/kg </p> </li> <li> <p><b>CG:</b> 29 placebo </p> </li> </ul> </li> <li> <p>Naive stratum (59 enroled):</p> <ul id="CD012623-list-0013"> <li> <p><b>IG:</b> 31 IFX 0, 2 and 6 weeks at 5 mg/kg </p> </li> <li> <p><b>CG:</b> 27 placebo </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(exclusion criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received steroids: 115</p> <p>All participants in the failure stratum were on and continued to use AZA:</p> <p>56/115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐ASA, budesonide, artificial nutrition or other immunosuppressive drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants were treated with AZA 2–3 mg/kg per day or 6‐MP 1.0–1.5 mg/kg per day. Participants previously treated with AZA or 6‐MP (failure stratum) continued their treatment at the same dose; in the naive‐stratum participants were treated with AZA 2.0–2.5 mg/kg per day, started 1 week after the first IFX infusion. The AZA or 6‐MP had to be maintained at a stable dose throughout the study, except for participants who experienced toxicity related to the drug. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg (0, 2 and 6 weeks) </p> <p><b>IG2:</b> IFX 10 mg/kg (0, 2 and 6 weeks) </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> (n = 31) </p> <p>Corticosteroids: 12<br/>6‐MP and AZA: 12<br/>5‐ASA: 17<br/>Antibiotics: 6 </p> <p><b>IG2:</b> (n = 32) </p> <p>Corticosteroids: 10 <br/>6‐MP and AZA: 17<br/>5‐ASA: 16<br/>Antibiotics: 11 </p> <p><b>CG:</b> (n = 31) </p> <p>Corticosteroids: 11<br/>6‐MP and AZA: 9<br/>5‐ASA: 19<br/>Antibiotics: 11 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclosporin (excluded from the start)</p> <p>IF not already on a stable dose of steroids/AZA/aminosalicylates/MTX medications had to have discontinued ≥ 4 weeks before enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1 + IG2:</b> </p> <p>Corticosteroids: 21<br/>6‐MP or AZA: 29<br/>5‐ASA: NR<br/>Antibiotics: 17 </p> <p>(the numbers were the same as medication up to study, so it seems most of the participants who were on these drugs continued throughout the study, although the paper did not state it) </p> <p><b>CG:</b> </p> <p>Corticosteroids: 11<br/>6‐MP or AZA: 9 <br/>5‐ASA: 19 <br/>Antibiotics: 11 </p> <p>Study reported IG1 and IG2, concomitant use</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg, IV, at weeks 14, 22, 30, 38 and 46. Beginning at week 22, participants who had a loss of response were eligible to cross over to maintenance treatment with IFX 10 mg/kg </p> <p><b>CG:</b> placebo (agent, dose and route: NR) at weeks 14, 22, 30, 38 and 46. Beginning at week 22, participants who had a loss of response were eligible to cross over to maintenance treatment with IFX 5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> single dose, IV, cA2 at 5 mg/kg </p> <p><b>IG2:</b> single dose, IV, cA2 at 10 mg/kg </p> <p><b>IG3:</b> single dose, IV, cA2 at 20 mg/kg </p> <p><b>CG:</b> single dose, IV, placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> <p><i>(exclusion criteria)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n per group (%)</p> <p>Prednisolone (&lt; 20 mg/day PO):</p> <p><b>IG1:</b> 8 </p> <p><b>IG2:</b> 8 </p> <p><b>IG3:</b> 10 </p> <p><b>CG:</b> 10 </p> <p>Prednisolone (≥ 20 mg/day PO):</p> <p><b>IG1:</b> 7 </p> <p><b>IG2:</b> 8 </p> <p><b>IG3:</b> 7 </p> <p><b>CG:</b> 6 </p> <p>6‐MP:</p> <p><b>IG1:</b> 4 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 4 </p> <p><b>CG:</b> 4 </p> <p>AZA:</p> <p><b>IG1:</b> 5 </p> <p><b>IG2:</b> 4 </p> <p><b>IG3:</b> 8 </p> <p><b>CG:</b> 7 </p> <p>5‐ASA:</p> <p><b>IG1:</b> 16 </p> <p><b>IG2:</b> 18 </p> <p><b>IG3:</b> 13 </p> <p><b>CG:</b> 17 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No numbers reported.</p> <p>Participants who were receiving 5‐ASA, corticosteroids, AZA or 6‐MP before the study continued to receive a stable dose during the trial period. </p> <p>The dose of corticosteroids could be tapered beginning 8 weeks after the initiation of the study. </p> <p>Treatment with these drugs or with MTX or ciclosporin could not be initiated during the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> CT‐P13 biosimilar 5 mg/kg </p> <p><b>CG:</b> IFX 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 54 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> </p> <p> <ul id="CD012623-list-0014"> <li> <p>Steroids 7/111 (33%)</p> </li> <li> <p>AZA 84/111 (76%)</p> </li> </ul> </p> <p><b>CG:</b> </p> <p> <ul id="CD012623-list-0015"> <li> <p>Steroids 33/109 (30%)</p> </li> <li> <p>AZA 80/109 (73%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>5‐ASA: 5‐aminosalicylic acid; 6‐MP: 6‐mercaptopurine; AZA: azathioprine; cA2: early name for infliximab; CG: control group; CT‐P13: subcutaneous infliximab; IFX: infliximab; IG: intervention group; IV: intravenous; MTX: methotrexate; n: number; NR: not reported; PO: oral; qd: once daily; TNF: tumour necrosis factor. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Included studies' intervention details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012623-tbl-0012"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Primary and secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Group interventions</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinical remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinical response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Withdrawals due to adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Endoscopic remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Histological remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Endoscopic response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0001" title="ColombelJF , ReinischW , MantzarisGJ , KornbluthA , RutgeertsP , TangKL , et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease – a SONIC post hoc analysis. Alimentary Pharmacology &amp; Therapeutics2015;41(8):734-46. ColombelJF , RutgeertsP , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzgD , et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Journal of Crohn's and Colitis2009;3(1):45-6. ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut2014;63(1):88-95. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. Peyrin-BirouletL , ReinischW , ColombelJF , MantzarisGJ , KornbluthA , DiamondR , et al. Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial. Journal of Crohn's and Colitis2013;7:S8. SandbornW , RutgeertsP , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases2009;15:s13. SandbornWJ , RutgeertsPJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology2009;136:751f. ">Colombel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> combination therapy </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>By week 26 (used in analysis)</p> <p><b>IG1:</b> 81/169 </p> <p><b>IG2:</b> 102/169 </p> <p><b>CG:</b> 54/170 </p> <p>By week 50</p> <p><b>IG1:</b> 64/169 </p> <p><b>IG2:</b> 80/169 </p> <p><b>CG:</b> 41/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI 70 response (week 26)</p> <p><b>IG1:</b> 95/169 </p> <p><b>IG2:</b> 113/169 </p> <p><b>CG:</b> 71/170 </p> <p>CDAI 70 response (week 50)</p> <p><b>IG1:</b> 75/169 </p> <p><b>IG2:</b> 88/169 </p> <p><b>CG:</b> 56/170 </p> <p>CDAI 100 response (week 26) used in analysis</p> <p><b>IG1:</b> 92/169 </p> <p><b>IG2:</b> 105/169 </p> <p><b>CG:</b> 64/170 </p> <p>CDAI 100 response (week 50)</p> <p><b>IG1:</b> 70/169 </p> <p><b>IG2:</b> 85/169 </p> <p><b>CG:</b> 47/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At week 54</p> <p><b>IG1:</b> 29/169 </p> <p><b>IG2:</b> 37/169 </p> <p><b>CG:</b> 42/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mucosal healing (week 26)</p> <p><b>IG1:</b> 28/169 </p> <p><b>IG2:</b> 47/169 </p> <p><b>CG:</b> 18/170 </p> <p><i>Randomised participants not assessed with endoscopy were counted as failures</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At week 54</p> <p><b>IG1:</b> 39/169 </p> <p><b>IG2:</b> 27/169 </p> <p><b>CG:</b> 43/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Through week 30</p> <p><b>IG1:</b> 41/169 </p> <p><b>IG2:</b> 39/169 </p> <p><b>CG:</b> 63/170 </p> <p>Through week 50</p> <p><b>IG1:</b> 53/169 </p> <p><b>IG2:</b> 53/169 </p> <p><b>CG:</b> 69/170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0002" title="D'HaensG , vanDeventerS , vanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029-34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg </p> <p><b>IG2:</b> IFX 10 mg </p> <p><b>IG3:</b> IFX 20 mg </p> <p><b>CG:</b> placebo 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR as dichotomous</p> <p>CDAI mean at week 4</p> <p><b>IG1:</b> 122.8 (SEM 26.1) </p> <p><b>IG2:</b> 220.5 (SEM 63.4) </p> <p><b>IG3:</b> 161.9 (SEM 34.5) </p> <p><b>CG:</b> 261.3 (SEM 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR as dichotomous</p> <p>CDEIS mean at week 4</p> <p><b>IG1:</b> 6.4 (SEM 5.1) </p> <p><b>IG2:</b> 4.3 (SEM 5.4) </p> <p><b>IG3:</b> 5.2 (SEM 2.8) </p> <p><b>CG:</b> 7.5 (SEM 5.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> <p>(except for 1 infliximab‐treated participant with exclusive rectosigmoidal Crohn's disease developed a new rectal stricture at the site of earlier severe ulceration) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0003" title="D'HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660-7. D'HaensGR , HommesD , BaertF , deVosM , CaenepeelF , vanAsscheG , et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology2006;130:110. ">D'Haens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg + AZA 2–2.5 mg/kg </p> <p><b>CG:</b> corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 14</p> <p><b>IG:</b> 43/67 </p> <p><b>CG:</b> 21/66 </p> <p>(taken from graph)</p> <p>After this time, infliximab was given to the CG and therefore no further data reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG</b> 14/67 </p> <p><b>CG</b> 14/66 </p> <p>at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR (only assessed post‐hoc)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG</b> 20/67 </p> <p><b>CG</b> 19/66 </p> <p><i>Not known at end of trial – we assumed that these occurred at 26 weeks</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear – numbers not reported per participant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0004" title="DuanZ , LuoJ , LiW . Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease. Chinese Journal of Gastroenterology2013;18(4):229-32. ">Duan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> AZA 2.5 mg/kg+ IFX 5 mg/kg </p> <p><b>CG:</b> AZA 2.5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission at week 26 – decrease in CDAI &lt; 70 points but a total CDAI score of &lt; 150 </p> <p><b>IG1:</b> 4/8 </p> <p><b>IG2:</b> 5/8 </p> <p><b>CG:</b> 3/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical efficacy at week 26 – decrease in CDAI ≥ 70 points or a decrease of ≥ 25% of the total CDAI score </p> <p><b>CG:</b> 2/8 </p> <p><b>IG1:</b> 2/8 </p> <p><b>IG2:</b> 2/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> 1/8 </p> <p><b>IG2:</b> 0/8 </p> <p><b>CG:</b> 1/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Fully healed"</p> <p><b>IG1:</b> 1/8 </p> <p><b>IG2:</b> 4/8 </p> <p><b>CG:</b> 3/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Basically healing"</p> <p><b>IG1:</b> 1/8 </p> <p><b>IG2:</b> 1/8 </p> <p><b>CG:</b> 1/8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0005" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541-9. ">Hanauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX infusion, regimen 1 </p> <p><b>IG2:</b> IFX infusion, regimen 2 </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0006" title="LemannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006;130(4):1054-61. ">Lemann 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 12</p> <p><b>IG:</b> 43/57 </p> <p><b>CG:</b> 22/58 </p> <p>Week 24 (primary)</p> <p><b>IG:</b> 32/57 </p> <p><b>CG:</b> 17/58 </p> <p>Week 52</p> <p><b>IG:</b> 23/57 </p> <p><b>CG:</b> 13/58 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 2/57 </p> <p><b>CG:</b> 5/58 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDEIS Decrease from baseline (median):</p> <p>Week 24:</p> <p><b>IG:</b> 6.9 (IQR 4.1 to 9.5) </p> <p><b>CG:</b> 1.2 (IQR −1.5 to 4.4) </p> <p>Dichotomous outcome only reported for a subset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 3/57 </p> <p><b>CG:</b> 3/58 </p> <p>Table 2 described "Serious adverse event in 5 cases (infliximab, n = 3; placebo, n = 3)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 29/57 </p> <p><b>CG:</b> 28/58 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0007" title="PresentDH , RutgeertsP , TarganS , HanauerSB , MayerL , vanHogezandRA , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine1999;340(18):1398-405. ">Present 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> IFX 5 mg/kg </p> <p><b>IG2:</b> IFX 10 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete response (defined as the absence of any draining fistulas at 2 consecutive visit) </p> <p><b>IG1:</b> 17/31 </p> <p><b>IG2:</b> 12/32 </p> <p><b>CG:</b> 4/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A reduction of ≥ 50% from baseline in the number of draining fistulas observed at ≥ 2 consecutive study visits </p> <p><b>IG1:</b> 21/31 </p> <p><b>IG2:</b> 18/32 </p> <p><b>CG:</b> 8/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> 1 </p> <p><b>IG2:</b> 1 </p> <p><b>CG:</b> 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 in total</p> <p><b>IG1:</b> 1/31 </p> <p><b>IG2:</b> 4/32 </p> <p><b>CG:</b> 0/31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> 10/31 </p> <p><b>IG2:</b> 26/32 </p> <p><b>CG:</b> 12/31 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0008" title="PapamichaelK , Vande CasteeleN , JeyarajahJ , JairathV , OstermanM , CheifetzAS . Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis. American Journal of Gastroenterology2021;116:1007-14. SandsBE , AndersonFH , BernsteinCN , CheyWY , FeaganBG , FedorakRN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine2004;350(9):876-85. ">Sands 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> IFX 5 mg/kg </p> <p><b>CG:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> 9/43 </p> <p><b>CG:</b> 7/44 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0009" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New England Journal of Medicine1997;337(15):1029-35. ">Targan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG1:</b> cA2 at 5 mg/kg </p> <p><b>IG2:</b> cA2 at 10 mg/kg </p> <p><b>IG3:</b> cA2 at 20 mg/kg </p> <p><b>CG:</b> 0.1% human serum albumin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &lt; 150 at week 4 (primary)</p> <p><b>IG1:</b> 19/27 </p> <p><b>IG2:</b> 11/28 </p> <p><b>IG3:</b> 11/28 </p> <p><b>CG:</b> 2/25 </p> <p>CDAI &lt; 150 at week 2</p> <p><b>IG1:</b> 16/27 </p> <p><b>IG2:</b> 10/28 </p> <p><b>IG3:</b> 10/28 </p> <p><b>CG:</b> 2/25 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 70‐point decrease clinical response at week 4</p> <p><b>IG1:</b> 22/27 </p> <p><b>IG2:</b> 14/28 </p> <p><b>IG3:</b> 18/28 </p> <p><b>CG:</b> 4/25 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012623-bbs2-0010" title="KimY , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. United European Gastroenterology Journal2017;5:1139-40. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results. Journal of Crohn's and Colitis2017;11:S62. KimYH , YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results. Gastroenterology2017;152:S65. YeBD , KimYH , PesegovaM , AlexeevaO , OsipenkoM , LahatA , et al. Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results. Gastroenterology2018;154:S-168. YeBD , LeszczyszynJ , DudkowiakR , LahatA , Ben-HorinS , Gawdis-WojnarskaB , et al. Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial. United European Gastroenterology Journal2020;8:385-6. YeBD , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevA , et al. Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet2019;393:1699-707. ">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IG:</b> CT‐P13 biosimilar 5 mg/kg </p> <p><b>CG:</b> IFX 5 mg/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission at weeks 6, 14, and 30</p> <p>Week 6 (primary)</p> <p><b>IG:</b> 47 </p> <p><b>CG:</b> 49 </p> <p>Week 14</p> <p><b>IG:</b> 59 </p> <p><b>CG:</b> 60 </p> <p>Week 30</p> <p><b>IG:</b> 61 </p> <p><b>CG:</b> 62 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 6</p> <p>CDAI‐70</p> <p><b>IG:</b> 77 </p> <p><b>CG:</b> 81 </p> <p>CDAI‐100</p> <p><b>IG:</b> 67 </p> <p><b>CG:</b> 70 </p> <p>Week 14</p> <p>CDAI‐70</p> <p><b>IG:</b> 96 </p> <p><b>CG:</b> 96 </p> <p>CDAI‐100</p> <p><b>IG:</b> 78 </p> <p><b>CG:</b> 83 </p> <p>Week 30</p> <p>CDAI‐70</p> <p><b>IG:</b> 85 </p> <p><b>CG:</b> 82 </p> <p>CDAI‐100</p> <p><b>IG:</b> 80 </p> <p><b>CG:</b> 80 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Up to 30 weeks</i> </p> <p><b>IG:</b> 17/111 </p> <p><b>CG:</b> 21/109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 30 weeks</p> <p><b>IG:</b> 6/111 </p> <p><b>CG:</b> 9/109 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 30 weeks</p> <p><b>IG:</b> 63/111 </p> <p><b>CG:</b> 70/109 </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AZA: azathioprine; cA2: early name for infliximab; CDAI: Crohn's Disease Activity Index; CDEIS: Crohn's Disease Endoscopic Index of Severity; CG: control group; IFX: infliximab; IG: intervention group; IQR: interquartile range; NR: not reported; SEM: standard error of the mean. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Primary and secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/full#CD012623-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Infliximab 5–10 mg/kg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clinical remission defined as CDAI &lt; 150 by week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [1.53, 13.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Clinical response defined as reduction of CDAI score by ≥ 70 at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.09 [1.63, 10.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Infliximab 5–10 mg/kg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical remission defined as absence of any draining fistulas at consecutive visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [1.38, 9.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Clinical response defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.10, 3.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.12, 50.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [0.31, 96.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.90, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Infliximab 5–10 mg/kg versus placebo for exclusively fistulating population</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Infliximab 5 mg/kg and purine analogues versus purine analogues</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Clinical remission as defined by the studies at weeks 24–26 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.59, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Clinical remission as defined by the studies (sensitivity analysis for fixed effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.59, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Clinical remission as defined by the studies (sensitivity analysis for biologically naive patients) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.56, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Clinical response as defined by the studies at week 26 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.31, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Endoscopic remission as defined by the studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.31, 3.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.55, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Infliximab 5 mg/kg and purine analogues versus purine analogues</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Infliximab 5 mg/kg versus purine analogues</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Clinical remission at week 26 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.15, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Clinical response at week 26 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.13, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.46, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Endoscopic remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.63, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.58, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Infliximab 5 mg/kg versus purine analogues</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Infliximab 5 mg/kg versus infliximab 10 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Clinical remission defined as CDAI &lt; 150 at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.06, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Clinical response defined as reduction in CDAI by 70 points at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.08, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Infliximab 5 mg/kg versus infliximab 10 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Clinical remission defined by closure of all fistulae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.84, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Clinical response defined as reduction of 50% in the number of draining fistulas at ≥ 2 consecutive visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.82, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 15.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.23, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Infliximab 5 mg/kg versus infliximab 10 mg/kg for exclusively fistulating population</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Infliximab 5 mg/kg versus infliximab 20 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Clinical remission defined as CDAI &lt; 150 at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.06, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Clinical response defined as reduction of CDAI score by ≥ 70 at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.91, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Infliximab 5 mg/kg versus infliximab 20 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Infliximab 10 mg/kg versus infliximab 20 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Clinical remission defined as CDAI &lt; 150 at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.52, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Clinical response defined as reduction of CDAI score by ≥ 70 at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Infliximab 10 mg/kg versus infliximab 20 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012623-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Infliximab 5 mg/kg versus biosimilar 5 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Clinical remission defined as CDAI &lt; 150 at week 6 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.72, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Clinical response defined as reduction of CDAI score by ≥ 100 at week 6 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.79, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.70, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.56, 4.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.91, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Infliximab 5 mg/kg versus biosimilar 5 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012623.pub2/references#CD012623-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012623.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012623-note-0025">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012623-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012623-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012623-note-0020">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD012623-note-0024">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD012623-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012623-note-0016">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012623-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012623-note-0023">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD012623-note-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012623-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012623-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012623\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012623\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012623\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012623\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012623\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012623.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012623.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012623.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012623.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012623.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717642129"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012623.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717642133"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012623.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbce6b9939371',t:'MTc0MDcxNzY0My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 